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Abstract 
 It has been reported that low dose sarin is associated with long-term pathology 
in the brain and heart; however, the effects of sarin on the heart have yet to be 
determined.  In addition, sarin has been implicated as an etiological agent in Gulf War 
Illness.  Thus, the role of sarin in producing illness has important military consequences. 
This study used echocardiography, electrocardiography, and histology to determine 
sarin’s effect on the murine cardiovascular system. C57BL/6J mice were injected with 
sarin at 0.4 LD50, 0.5 LD50, or saline on two consecutive days and studied for 10 weeks 
post exposure.  The sarin animals had marked increases in heart weight to body weight 
ratios (p = 0.026), and the left ventricular lumen size was significantly decreased (p = 
0.0014).  In addition, cardiomyocytes were significantly larger in the sarin mice (p = 
0.025) and atrial/brain natriuretic peptide levels were increased (p = 0.028 and 0.010, 
respectively).  Results of the electrocardiograms show significant ST/T-wave changes in 
the sarin groups (p = 0.0015 and 0.032, respectively).  Similarly, echocardiograms 
showed significantly decreased performance of the left ventricle in the sarin animals.  
This study indicates that sarin plays a role in cardiac remodeling and reducing cardiac 
performance.   
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LOW DOSE SARIN LEADS TO MURINE CARDIAC DYSFUNCTION 
I. Introduction 
A Brief Review on the Toxicology of Sarin 
Sarin belongs to the chemical class known as organophosphates (OP).  OPs are a 
group of chemical toxins that inhibit acetylcholinesterase (AChE) and are widely used as 
pesticides and chemical warfare agents (CWA).  Sarin, O-isopropyl methylphosphono- 
fluoridate (military designation – GB), acts as an irreversible AChE inhibitor. Sarin reacts 
with the serine hydroxyl residue in the active site of AChE to form a phosphate or 
phosphonate ester; hence the AChE is inhibited (or deactivated). Deactivated AChE 
cannot hydrolyze the cholinergic neurotransmitter Acetylcholine (ACh) resulting in its 
accumulation and excessive stimulation of cholinergic receptors. Overstimulation of 
central and peripheral cholinergic sites occurs in smooth muscles, skeletal muscles, 
most exocrine glands, the central nervous system (CNS), and the cardiac system (central 
and ganglionic afferents).  
Stimulation of muscarinic receptors at the smooth muscle level causes miosis, 
bronchoconstriction, vasodilation, increased peristalsis, and reduced heart rate at 
smooth muscle level; at exocrine glands, it causes secretions in the lung, nasal, oral, and 
sweat glands. Among clinical effects due to nicotinic receptor overstimulation at skeletal 
muscle are fasciculation, twitching, flaccid paralysis and stimulation of autonomic 
ganglia leading to tachycardia and hypertension. The CNS has both muscarinic and 
nicotinic receptors and overstimulation leads to seizures and can cause death; whereas, 
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a mild exposure leads to variety of symptoms which include forgetfulness, bad dreams, 
insomnia, and the ability to concentrate.  
Sarin reacts with the cardiovascular system in a complex manner; effects are 
comprised of both ganglion and postganglionic consequences of accumulated ACh on 
the heart and blood vessels. The overall acute effect on the heart depends on the 
relative prevalence of sympathetic or parasympathetic effects. Cholinergic effects from 
ACh suppress vagal tone resulting in a decreased refractory period and conduction time 
at sinoatrial (SA) and atrioventricular (AV) nodes; whereas, excess ACh also affects the 
muscarinic ACh M2 receptors in the heart leading to negative chronotropic and 
ionotropic effects.  Thus, ACh creates contradicting excitatory effects on 
parasympathetic ganglionic cells in the face of the inhibitory effects of the sympathetic 
ganglia.  ACh elicits similar excitatory followed by inhibitory effects at the medullary 
vasomotor and cardiac centers. In severe ACh accumulation, hypoxia resulting from 
bronco-constriction also affects the cardiovascular system by reinforcing sympathetic 
tone, while ACh induced epinephrine released from adrenals leads to increased heart 
rate.  As a result, sarin induces bradycardia, tachycardia, and arrhythmias in the heart 
that can lead to spontaneous cardiac failure (Taylor, 2001; Marrs, 2007). 
Historical Perspective on the Use and Implications of Sarin to the US Military 
The United States Air Force has become increasingly engaged with terrorist 
groups and other elusive enemies.  As these activities increase, the potential for 
adversarial use of chemical weapons increases.  Terrorist groups and other third world 
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countries have decisive conventional and technological disadvantages.  As such, 
weapons of mass destruction proliferators could significantly ameliorate their tactical 
and strategic positions through the use of chemical weapons.   
     In the literature, there are several examples of the use of or potential use of 
sarin to gain an asymmetric advantage.  During the 1980-1988 Iraq-Iran war both Iraq 
and Iran employed chemical weapons (including sarin) in an attempt to gain an 
advantage in a seemingly unending war (Ali, 2001).  In addition to Iraq and Iran, the 
Japanese have experienced two separate terrorist attacks involving sarin. The first 
occurred in 1994 when nearly 600 Japanese citizens were exposed to sarin in an attack 
in a neighborhood of Matsumoto, Japan (Committee on Gulf War and Health: Updated 
Literature Review of Sarin, 2004).  In 1995, the Aum Shinrikyo terrorist group deployed 
the chemical agent sarin against a civilian population as an attempt to divert police 
attempts to prostrate the organization.  As a specific threat to the US, in 2001, Al Qaeda 
claimed acquisition of radiological, biological, and chemical weapons.  The threat was 
deemed credible when videotapes aired in 2002 showing the ostensible killing of three 
dogs by a nerve agent (Robertson, 2002). These events demonstrate the intent and 
willingness of such organizations to employ chemical weapons.  
  Sarin became a particularly important topic in the US following the 1990 US-Iraq 
Gulf War.  During the Gulf War, three sites were destroyed where munitions loaded 
with sarin and cyclosarin were stored.  Of the three sites, plume models show that only 
the Khamisiyah site had the potential for US troop exposure (see Figure 1 and 2).   
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Figure 1 Demolition of bunkers at Khamisiyah, 4 March 1991 
(Central Intelligence Agency; Department of Defense, 
1997) 
 
Figure 2 Plume Models for the Demolition of 
Bunkers at Khamisiyah, 12 March 1991 
(Persian Gulf War Illnesses Task 
Force, 1997) 
According to estimates, nearly 90,000 troops may have been exposed to sarin and 
cyclosarin as a result of the demolitions (Committee on Gulf War and Health: Updated 
Literature Review of Sarin, 2004). US troops performing demolitions were unaware of 
the presence of nerve agents because their detectors, being sensitive only to lethal or 
near-lethal concentrations of nerve agents, did not sound any alarms before demolition 
(CDC, 1999, p. 55).  As a result, sarin and other organophosphate nerve agents were 
implicated as a possible etiological agent in Gulf War Illness (GWI) and subsequently 
investigated by the US Department of Veterans Affairs (Couzin, 2004). 
Sarin Health Effects and Gulf War Illness 
  Gulf War veterans show a variety of poorly defined neurological, muscular and 
autonomic symptoms including poorer cognitive function, tiredness, muscle and joint 
pain, loss of balance, bladder dysfunction, and diarrhea (Jamal, 1998; Jamal, Hansen, 
Apartopoulos, & Peden, 1996).  Studies of Gulf War veterans show altered diurnal 
patterns of HR and HR variability correlated to reduced parasympathetic drive to the 
heart possibly resulting from damage to the CNS (Haley, Fleckenstein, Marshall, 
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McDonald, Kramer, & Petty, 2000; Haley, et al., 2004; Menon, Nasrallah, Reeves, & Ali, 
2004), and autonomic imbalance is a common symptom in sarin poisoning (Yokoyama, 
et al., 1998, pp. 317 - 323).  Previous reports have shown comparable delayed 
autonomic effects of low dose sarin exposure in mice and rats (Morris, Key, & Farah, 
2007; Grauer, et al., 2008).  Recently, some human data from the Aum Shinrikyo-Tokyo 
subway attacks has indicated that sarin could produce neurological and autonomic 
changes (Murata, et al., 1997; Yokoyama, et al., 1998, pp. 249 - 256; Yokoyama, et al., 
1998, pp. 317 - 323).  Similarly, Haley et al. have shown similar symptoms in veterans 
exhibiting GWI (Haley, Kurt, & Hom, 1997).  Nonetheless, although the latter proposes a 
link between nerve agents and GWI, there are almost no records on the source or level 
of exposure; the evidence is inconclusive and more data is needed (Committee on Gulf 
War and Health: Updated Literature Review of Sarin, 2004). 
Specific Effects of Sarin Relevant to the US Military and Civilian Populations 
While it is expected that potent, cholinergic poisoning would cause pathological 
changes, it is more likely that the majority of survivors following a sarin release would 
have been exposed to a much lower or even asymptomatic dose.  There is evidence that 
even an exposure to a non-symptomatic dose causes long-term changes.  Unfortunately, 
toxicological data for late onset low dose organophosphate exposure effects is sparse.  
Studies of cardiotoxicity due to OP poisoning have demonstrated long-term QT 
prolongation, arrhythmias, various conduction problems, cardiomyopathy, and sudden 
death (Alaoui, Mossadeq, Faroudy, & Sbihi, 2009; Bar-Meir, et al., 2007; Gohel, Oza, 
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Panjwani, & Gajjar, 1996; Marosi, Ivan, Vass, Gajdacs, & Ugocsai, 1989; Kiss & Fazekas, 
1979).  
Studies involving sarin in rodents report susceptibility to epinephrine induced 
arrhythmia and long QT syndrome for initial period of four weeks from the single whole 
body exposure to sarin in rats (Allon, Rabinovitz, Manistersky, Weissman, & Grauer, 
2005).  Another study in rats shows QT prolongation and cardiac lesions for up to 12 
weeks following a slightly higher dose sarin dose (Abraham, Oz, Sahar, & Kadar, 2001).  
Other low dose long-term changes have been reported in rats to include DNA synthesis, 
and brain cholinergic receptors and genetic expression (Kassa, et al., 2004; Damodaran, 
Jones, Patel, & Abou-Donia, 2003; Jones, Dechkovskaia, Herrick, Abdel-Rahman, Khan, & 
Abou-Donia, 2000).  Recently, Morris et al. and Joaquim et al. have linked autonomic 
changes with the heart; showing an increase in heart rate variability (HRV) following an 
AChE inhibition (Morris, Key, & Farah, 2007; Joaquim, Farah, Bernatova, Rubens Jr., 
Grubbs, & Morris, 2004). As with the GWI data, the literature lacks sufficient 
toxicological background to pinpoint the risk to the heart following a low/asymptomatic 
dose of nerve agent.   
Problem Statement  
The current literature lacks sufficient background on low dose and late-onset 
effects resulting from exposures to sarin or other OPs. Understanding these effects has 
significant interest to the military – from both a GWI perspective as well as performing 
military operations in a chemical agent environment.  Current Air Force doctrine allows 
for selective chemical protection (known as split-MOPP (Mission Oriented Protective 
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Posture)) following a chemical warfare agent attack (United States Air Force, 2007).  At 
present, the literature is vague as to the long-term risk split-MOPP may pose to military 
forces that might receive an asymptomatic dose of nerve agent when not wearing their 
chemical protection equipment.  Additionally, as seen in the Gulf War, munitions 
demolition poses a risk to US military personnel (CDC, 1999).  
The Japanese terrorists’ attacks of 1994 and 1995 demonstrate that civilians are 
at risk as well.  In addition, nearly all the known living humans with sarin exposures were 
victims of Japanese terrorists’ attacks, and these attacks are the source of the bulk of 
the literature on human exposures. Unfortunately, there is little documentation on the 
extent of exposure in these cases (Committee on Gulf War and Health: Updated 
Literature Review of Sarin, 2004). Thus researchers must rely on animal studies to 
investigate long-term sarin effects.  
The literature, however, has few descriptive and long-term cardio-toxicological 
studies following a low dose sarin exposure.  Recent high dose studies have shown a link 
between sarin and long-term electrocardiogram (ECG) changes in rats.  Similarly, OP 
poisonings (high-dose) have shown long-term cardiovascular changes to include ECG 
abnormalities (e.g. QT prolongation), cardiomyopathy, and arrhythmias.  No study (to 
the author’s knowledge), however, has combined echocardiography and histology/ 
morphology evidence with ECG.   
In summary, data is scarce concerning low dose sarin, long-term effects on the 
cardio-vascular system (CVS), and relating to molecular/morphological changes in the 
heart.  In addition, the conduction abnormalities observed at high doses of sarin need to 
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be critically analyzed at low doses to help provide early diagnosis. Similarly, functional 
and structural changes in the heart have not been evaluated.  Finally, CVS studies thus 
far have analyzed the heart under basal conditions; assessment of CVS under stressed 
conditions is known to provide invaluable information regarding response of CVS under 
load (i.e. stress of running). 
Research Objective/Hypothesis  
Subclinical doses (0.4 LD50 and 0.5 LD50 on two consecutive days) of sarin cause 
cardiac remodeling/performance degradation over a period of time. 
Specific Aims:  
1) To test the hypothesis that low dose Sarin causes delayed cardiac remodeling. 
2) To test the hypothesis that low dose Sarin has a negative effect on cardiac 
performance over a period of time. 
3) To test the hypothesis that subtle effects from low dose Sarin will become 
apparent as a result of stressing. 
Proposed Experiment 
C57BL/6J strain mice will be injected on two consecutive days with saline 
(controls), 0.4, or 0.5 times the LD50 for sarin, and will be studied for cardiac pathology.  
Mice cholinesterase levels will be measured 24 hours post exposure to confirm the 
effect of the sarin injection levels.  The mice will be studied for 10 weeks after exposure, 
sacrificed, and relevant tissues and organs collected.  A short-acting β1 specific agonist, 
dobutamine, will be used to create stress in the heart.  2-D and 2-D M-mode 
echocardiography will be used to measure left ventricular structure and performance 
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before and after a dobutamine stress test at two, four, and 10 wks.  Additionally, 
electrocardiogram tracings will be obtained at the 10-week point, baseline and after 
dobutamine.  Finally, histological methods, such as atrial natriuretic peptide (ANP), brain 
natriuretic peptide (BNP), and collagen staining will be used to determine additional 
measures of pathology. 
Contributions 
The contribution of this research is to close the gap between the current 
literature and the effects of low dose sarin.  Where the current literature suggests that 
sarin causes cardiac dysfunction, more analysis is required to link low dose sarin to long-
term cardiac impairment.  This research will focus on cardiac pathology with an in-depth 
temporal evaluation of murine cardiac performance; combining, toxicological 
techniques to include histology, echocardiography, and ECGs.  As such, this study will 
provide important parameters to the medical community in the diagnosis following a 
sarin exposure, and allow the military to develop post deployment health assessments 
with late-onset pathology in mind.  
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II. Literature Review 
Introduction 
 Studies have expressed ECG changes in rodents and humans following acute 
exposures to sarin and OPs indicating cardiovascular changes.  Yet, the literature is 
lacking with regard to cardiac morphology and other fundamental changes.  As such, 
this study presents a first look at cardiac performance and morphological parameters 
under a variety of conditions.  The following discussion communicates the importance of 
these parameters and conditions as described in the current literature. 
Animal Considerations 
 Unlike humans, mice have high levels of carboxylesterase which rapidly degrades 
sarin and modifies the dose-response curve (Li, et al., 2005; Jokanovic, Kosanovic, & 
Maksimovic, 1996).  In order to reduce the effect of carboxylesterase, the animal’s 
susceptibility to sarin can be enhanced by dosing on consecutive days.  The first dose 
consumes serum carboxylesterase so that the second dose has greater effect on the 
cholinergic receptors; thus making the toxicity curve more similar to that seen in 
humans.  In order to ensure this effect, serum cholinesterase (ChE) assays are used to 
ensure adequate depression of ChE levels (Sidell & Borak, 1992).  
Choice of Anesthesia and Expected Effects 
 The use of anesthesia has been shown to have a significant effect on 
echocardiograms and ECGs when compared to conscious mice.  In echocardiograms, the 
studies have shown decreased cardiac performance such as heart rate variability, 
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fraction shortening, and ejection fraction.  (Tan, et al., 2003; Stein, et al., 2005; Roth, 
Swaney, Dalton, Gilpin, & Ross Jr, 2002).  Similarly, ECG tracings have shown significant 
decreases in heart rate, and increases in QT and PR intervals (Chavesa, Dech, Nakayama, 
Hamlin, Bauera, & Carnes, 2003).   
Nevertheless, Tan et al. have shown that the use of sedatives may help to reduce 
stress and significantly reduce the variability seen in echocardiograms using conscious 
mice; this is apparently due to stress differences created because of restraints or the 
amount of training the mice received (Tan, et al., 2003).  Additionally, Roth et al. quote 
several sources in the literature that have been unable to record images in conscious 
mice due extremely high heart rates (stress induced despite training) and the difficulty 
of transducer placement in conscious animals (due to small movements).  Therefore, the 
difficulty of transducer placement and training, variations in sympathetic and 
parasympathetic tone during restraint, and relatively high HR make measurements in 
conscious mice less than ideal for all applications of echocardiography (Roth, Swaney, 
Dalton, Gilpin, & Ross Jr, 2002; Tan, et al., 2003).  Furthermore, the use of restraints in 
mice has been shown to increase body temperature, heart rate, blood pressure, plasma 
epinephrine/nor-epinephrine levels, and change responses to pharmaceuticals (Kramer, 
Kinter, Brockway, Voss, Remie, & Van Zutphen, 2001).  Similar findings have been found 
in ECG recordings; movement artifacts, animal acclimation, and the ability to only 
capture very short ECG recordings have been listed as some of the drawbacks of using 
conscious animals (Chavesa, Dech, Nakayama, Hamlin, Bauera, & Carnes, 2003).  Finally, 
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the use of conscious animals requires implantation of the ECG probes or restraint, and 
implantation is a costly alternative to the use of anesthesia. 
 Of the anesthesia widely used in the literature, isoflurane (ISF) has been shown 
to affect the heart less than other anesthesia in echocardiograms and ECGs (Tan, et al., 
2003; Stein, et al., 2005; Roth, Swaney, Dalton, Gilpin, & Ross Jr, 2002; Chavesa, Dech, 
Nakayama, Hamlin, Bauera, & Carnes, 2003).  Additionally, Stein et al. have cited that 
ISF is easier to use, produces reproducible results, has short-lived action, and is ideal for 
multiple short lived experiments (Stein, et al., 2005).  Given the drawbacks of using 
conscious animals and the advantages of ISF, ISF was chosen for use in this experiment.  
Because all of the animals will be anesthetized in the same manner, the use of 
anesthesia is thought to have minimal (if any) impact on the experimental outcomes.  
Environmental Concerns 
 Temperature has been shown to significantly influence murine cardiac 
performance.  Hartley et al. have shown fluctuation of body temperature during surgical 
and monitoring procedures under anesthesia.  As mice are unable to maintain body 
temperature under ISF, significant alterations occur in heart rate and cardiac function 
with changes in body temperature (Hartley, Michael, & Entman, 1995; Hartley, Taffet, 
Reddy, Entman, & Michael, 2002).  Likewise, Swoap et al. have shown that variations in 
room temperature (as small as 4oC) can significantly affect heart rate and blood 
pressure in a mouse (Swoap, Overton, & Garber, 2004).  For these reasons, all 
procedures are carried out in a temperature controlled room (22oC ± 1oC), and a heating 
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blanket will be used to ensure body temperature is maintained throughout all 
procedures.  Finally, as with the anesthesia, all of the animals will be maintained in the 
same manner, and temperature effects are thought to have minimal (if any) impact on 
the experimental outcomes.  
Dobutamine Stress Testing 
 In order to test stimulated heart function in mice, a low dose (1 mg/kg) of 
dobutamine will be injected.  Dobutamine, a short-acting and preferential β1 adrenergic 
agonist (Anderson, Moore, & Larson, 2008; Daly, Linares, Smith, Starling, & Supiano, 
1997), is widely used in the analysis and stratification of cardiac function under stress 
(Mertes, et al., 1993; Shaheen, Luria, Klutstein, Rosenmann, & Tzivoni, 1998).  
Dobutamine increases heart rate, contractility, and cardiac output (Wiesmann, et al., 
2001; Weissman, Levangie, Guerrero, Weyman, & Picard, 1996), and its effects last for 
approximately 25 minutes (Wiesmann, et al., 2001).  By creating positive ionotropic and 
chronotropic effects, the β-agonist increases myocardial oxygen demands, producing 
abnormalities (otherwise not apparent) that appear in ECG and echocardiography as the 
result of the supply-demand mismatch (Weissman, Levangie, Guerrero, Weyman, & 
Picard, 1996).  Additionally, because dobutamine preferentially binds β1-
adrenoreceptors, the stress test can offer information on the overall health of the 
receptor cascade (Anderson, Moore, & Larson, 2008).   
In general, dobutamine has not been shown to have any long lasting effects, 
however Anderson et al. have shown that large doses (40 μg/mouse/day for seven days) 
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can increase fibrosis and lead to hypertrophy (Anderson, Moore, & Larson, 2008).  This 
experiment will use low doses (1 mg/kg body weight, or approx. 30 μg/mouse), and 
each mouse will only be injected 3 times (at the 2, 4, and 10 week points); thus the mice 
should not be subject to any long-term effects.  Therefore, dobutamine offers a readily 
reproduced method of measuring cardiac performance under stressful conditions.  
Noninvasive In Vivo Measurements  
Echocardiograms 
 Echocardiography is a commonly used technique to give important geometric 
and temporal information about the heart.  Imaging techniques have been adapted 
from human systems (and imaging systems designed for larger animals) and usually 
have less than ideal temporal resolutions (frame rates) when used with mice (human 
rate is near 60 beats per minute whereas murine heart rate is as high as 600). 
Nonetheless, echocardiography is one of the most widely used noninvasive techniques 
for testing murine cardiac function (Hartley, Taffet, Reddy, Entman, & Michael, 2002).  
Long axis views of 2-Dimensional (2-D) and guided M-mode are frequently 
acquired parameters to give area and diameter measurements of the left ventricle (LV) 
and LV walls in systole and diastole (Schiller & Foster, 1996; Morgan, et al., 2004).  Other 
important derived parameters (e.g. area fractional shortening (aFS)) can be calculated 
from the long axis end systolic and diastolic areas (ESA and EDA) and diameters (ESD 
and EDD).  Such derived parameters are well documented and reproducible indicators of 
LV and cardiac function (Morgan, et al., 2004).  Pulse wave Doppler imaging of trans-
mitral flow provides time profiling, and is useful for calculating a variety of parameters 
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related to ventricular dysfunction such as myocardial performance index or MPI (Tei, 
Nishimura, Seward, & Tajik, 1997; Syed, Diwan, & Hahn, 2005).  Combinations of the 
above parameters (2 D, M-mode and Doppler) can be used to obtain a pressure-
independent measure of LV contractile function such as velocity of circumferential fiber 
shortening (Vcf) and aFS/MPI.  These combined parameters serve as superior indicators 
of overall LV function since these values take into account both geometric and temporal 
measures of LV function (Broberg, et al., 2003; Syed, Diwan, & Hahn, 2005). 
Electrocardiograms (ECG) 
 Electrocardiograms are used in humans to detect a multitude of cardiac 
problems to include bradycardia, tachycardia, atrioventricular (AV) block, ischemia, 
Torsades de Pointes (also known as long QT syndrome), and other arrhythmic 
dysfunctions (Roden, 2001).  In general, ECGs measure the impulse propagation through 
the conduction system.  Cardiac impulses originate in the sinus node and depolarizing 
currents (Na+ – K+ exchange) spread anisotropically from the sinus node.  Upon leaving 
the sinus node, the impulse rapidly propagates throughout the atria, resulting in the P-
wave (atrial systole) seen on the ECG (see Figure 3).  Propagation is then markedly 
slowed through the AV node where inward Ca+ channels are much smaller than the Na+ 
current in the atria.  This delay, corresponding to the PR interval on the ECG, allows the 
atrial contraction sufficient time to fill the ventricle.  As the impulse leaves the AV node, 
the propagation rate is substantially increased (through large Na+ channels) and 
ventricular contraction ensues (forming the QRS complex on the ECG) as impulses race 
through the Bundle of His to the Purkinje Fibers.  Finally, the ventricle relaxes (ST 
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segment in the ECG) and then undergoes repolarization, forming the T-wave on the 
ECG; after which the impulses diffuse from the endocardium to the epicardium forming 
the iso-volumetric relaxation time (inactivity on the ECG from T-end to start of the P-
wave).  Thus, the PR interval on the ECG corresponds to the AV nodal conduction time, 
the QRS complex represents the ventricular conduction time, and the QT interval 
describes the complete ventricular action potential (Roden, 2001).  As such, the ECG is 
an excellent measure of the overall health of a cardiac system. 
 The first ECGs in mice were reported nearly 70 years ago (Hartley, Taffet, Reddy, 
Entman, & Michael, 2002), and the progress of ECG studies in mice has been 
summarized by Wehrens et al. (Wehrens, Kirchhoff, & Doevendans, 2000).  With the 
exception of the T-wave, mice ECGs are similar to the human ECG (see Figure 4).   
 
 
Figure 3 Typical Human ECG 
(This image is licensed for unrestricted 
redistribution (Atkielski, 2007)). 
 
 
Figure 4 Typical Mouse ECG Illustrating the Difference in 
the T-wave when Compared to the Human ECG 
 
T-wave merged
with QRS
T-wave peak
T-wave end
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In mice, the T-wave merges with the end of the QRS complex and the ST segment is not 
discernable (Wehrens, Kirchhoff, & Doevendans, 2000; Mitchell, Jeron, & Koren, 1998; 
London, 2001).  This merged T-wave rises above the iso-electric line and has a long tail 
that falls below the iso-electric line before returning to mark the iso-volumetric 
relaxation time (Mitchell, Jeron, & Koren, 1998).  Despite these differences, the ECG 
represents a valuable diagnostic tool for overall health of the murine cardiovascular 
system and has widely been used in literature to detect dysfunctions in mice analogous 
to those seen in humans, i.e. ischemia, Torsades de Pointes, etc. (Kramer, van Acker, 
Voss, Grimbergen, van der Vijgh, & Blast, 1993; Hartley, Taffet, Reddy, Entman, & 
Michael, 2002; Mitchell, Jeron, & Koren, 1998; Wehrens, Kirchhoff, & Doevendans, 
2000).  
In Vitro/Histological Markers  
Utility of ANP/BNP Measurements  
Atrial natriuretic peptide and Brain natriuretic peptide (ANP and BNP) are 
hormones synthesized and secreted exclusively by the heart as a response to activation 
of hormonal or mechanical stimuli that occur during heart failure and ventricular 
dysfunction (Yasuno, et al., 2009).  ANP/BNP function as cardiac contractile genes up-
regulated during cardiac remodeling and are indicative of various pathologies such as 
cardiomyopathy, hypertrophy and heart failure, etc.  ANP is synthesized in atrial 
myocytes, whereas, BNP is synthesized in ventricular myocytes; ANP/BNP increase as a 
response to wall stretch and cardiac stress (Goetze, Georg, Jorgensen, & Fahrenkrug, 
2009; Mair, 2008).   
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ANP and BNP regulate blood pressure by vasodilatation and increasing the 
permeability of vasculature.  Both ANP and BNP exert their natriuretic, diuretic, and 
vasorelaxant effects through activation of their common receptor Natriuretic Peptide 
Receptor A (NPRA) (Kawakami, et al., 2010).  Studies in mice have shown protective role 
of ANP and BNP in models of dilated cardiomyopathy and of sudden death in guanylyl 
cyclase-A knockout (GC-A -/-) mice (Yasuno, et al., 2009).  In addition, ANP is also shown 
to have growth inhibitory response in cardiac myocytes and fibroblasts upon stimulation 
by nor-epinephrin (Knowles, et al., 2001; Tamura, et al., 2000).  Similarly, a NPRA 
knockout study (NPR -/-) shows development of hypertrophy independent of pressure 
overload (presumably solely due to the missing ANP/BNP receptor) (Scott, et al., 2009). 
Furthermore, ANP/BNP, also known as a subset of fetal cardiac genes, are expressed in 
fetal ventricles during development but are quiescent in adult ventricles (Scott, et al., 
2009).  Therefore, increased ANP/BNP levels in adult mice serve as excellent biomarkers 
of overall cardiac health, and are a likely indicator of cardiac detriment because of sarin 
exposure. 
Collagen and Picrosirius Red Staining 
Fibroblasts are widely recognized as a critical cell type involved in wound healing 
and tissue repair.  During repair functions, quiescent fibroblasts are transformed into 
active myofibroblasts (smooth muscle-like fibroblasts) (Long & Brown, 2002; Powell, 
Mifflin, Valentich, Crowe, Saada, & West, 1999).  In the heart, myofibroblasts produce 
collagen in response to an insult or infraction (Kerckhovena, Kalkmana, Saxenaa, & 
Schoemaker, 2000; Lutgens, Daemen, Muinck, Debets, Leenders, & Smits, 1999).  As 
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such, cardiac fibrosis is characterized predominantly by over expression of collagen 
types I, II, and III, into the interstitial and perivascular space (Diez, Lopez, Gonzadlez, & 
Querejeta, 2001).  Excessive collagen deposition leads to myocardial stiffening, impaired 
cardiac relaxation and filling (diastolic dysfunction), and overload of the heart (Swaney, 
Roth, Olson, Naugle, Meszaros, & Insel, 2005).  Therefore, increased collagen levels 
serve as a good indicator of cardiac insult.  
 Finally, Picrosirius Red is a highly specific dye for collagen fibers.  Under cross-
polarized light thicker strands of collagen appear yellow to orange, thinner fibers green, 
and the background is black.  This birefringence is largely due to type I collagen. 
(Junqueira, Bignolas, & Brentani, 1979; Puchtler, Waldrop, & Valentine, 1973). 
Hematoxylin and Eosin (H&E) Staining 
 H&E is a prevalent stain used in preparation of histology slides.  H&E stains 
nuclei blue and the rest of the cell (cytoplasm, collagen, muscle fibers) is stained pink 
(Eroschenko, 2008).  As such, the H&E stain provides important information about the 
nuclei and muscle fiber arrangement and cell size when heart sections are examined 
under a microscope. 
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III. Methodology 
Animal Experimental Protocol 
Thirty-six male C57BL/6J mice were housed individually at 22°C with a 12:12-
hour dark-light cycle.  Mice had free access to a standard diet and tap water.  Mice were 
injected with sarin: 64µg/kg (0.4 LD50 – lethal dose to 50 percent of the population) and 
80 µg/kg (0.5 LD50), respectively, or saline (control group) on two consecutive days.  
Each group (controls, 0.4 LD50, and 0.5 LD50) originally consisted of twelve mice.  Mice 
body weights were collected 24 hours, four weeks, seven weeks, and 10 weeks following 
the sarin injections. 
 In order to ensure that the sarin dose affected the mice, blood cholinesterase 
levels were measured 24 hours after the second sarin injection using a modified version 
of the assay developed by Ellman et al. (Ellman, Courtney, Andres, & Feather-Stone, 
1961).  Blood was obtained by cheek puncture, mixed with tetraisopropylpyrophosphor-
amide (iso-OMPA), and diluted with a sodium phosphate buffer solution.  This mixture 
was incubated and then dithionitrotoluene (DTNB) and acetylthiocholine (ATCh) were 
added.  Total ChE was measured in the same manner with the exception that sodium 
phosphate was added in lieu of iso-OMPA.  These samples were measured using a 
Fusion™ Microplate Analyzer (Packard Bioscience Company, Meriden, CT).  Butyryl ChE 
was determined as total ChE less the AChE.  Figure 5 demonstrates that average ChE 
levels were approximately 50 percent of the original level in both sarin affected 
populations. 
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Figure 5 Blood Cholinesterase Levels 24 Hours after 2 Consecutive Sarin Injections 
 Following the second sarin injection, a total of six of the 12 0.5 LD50 group seized 
and died; no mice from the 0.4 LD50 group died, but three seized following the second 
injection.  Throughout the 10 weeks one control mouse died, two of the 0.4 LD50 group, 
and one more from the 0.5 LD50 group died.  
Tissue Collection, Heart Sectioning, and Heart Size Measurement Methods 
 In the 10th week after sarin infusion, the mice were sacrificed (following ECG and 
echocardiogram recordings) by decapitation.  Immediately following decapitation, the 
heart was collected, weighed, and relaxed in a phosphate buffered saline (PBS) solution. 
The apex was removed using a straight razor and the heart (sans apex) was placed in a 
4% paraformaldehyde (PFA) solution.  This solution was stored at 4 0C for 48 hours.  
Following the 48 hour adsorption time, the hearts were removed from the PFA and fixed 
in a 20% sucrose/4% PFA solution.  Hearts were stored for an additional 24 hours at 4 
degrees Celsius, and then transferred to a -80 degree Celsius freezer where they were 
stored until they were shipped to AML Laboratories, Inc for cryostat sectioning.   
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Prior to shipment, a random selection of the fixed mouse hearts (7 control; 8, 0.4 
LD50; and 5, 0.5 LD50) was selected for cryostat sectioning.  Three-millimeter sections of 
the left and right ventricle were created using a 1 mm heart block (Zivic Laboratories, 
Inc., Pittsburg, PA.).  The hearts were held in place using a razor blade and forceps while 
sectioning (Figure 6).   
 
Figure 6 Representative 3mm Heart Sectioning 
Photographs were taken of the atrial side (larger side nearest the atriums) from 
each section.  A Nikon D50 camera (Chiyoda-ku, Tokyo) with an AF-Micro Nikkor® 60mm 
lens was used to take each photograph.  A ruler (with 1 mm sections) was included in 
the photograph to provide a reference for size measurements (see Figure 7).   
 
Figure 7 Picture of Atrial Side of a 3mm Thick Heart LV/RV section 
All pictures were taken the same day, with the same light settings and camera settings.  
The camera was mounted and sections were placed on the same reference point to 
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ensure that the camera perspective remained the same.  These three-millimeter 
sections were sent to AML Laboratories, Inc. (Rosedale, MD) where five-micron paraffin 
slides of the sections were created from the atrial side of the ventricles. 
Heart Section Size Measurements 
 Total heart, LV, and RV area were calculated using the Adobe® (San Jose, CA) 
Photoshop® CS3 software package (version 10.0.1).  A single, blinded observer 
performed all the analysis on a single day.  The RV and LV were manually cropped from 
the heart sections using the quick selection and magic wand tool sets (see Figure 8).  
Cropped sections were pasted into a new blank image with transparent pixels, and the 
total area (in pixels) was obtained via the programs histogram tool.  After the ventricles 
were cropped, the heart section was selected (using the quick selection/magic wand 
tools as described above) and pasted into a blank image with transparent pixels; the 
histogram tool was used to calculate the total heart area. 
 
Figure 8 Representation of manual Cropping of the RV 
and LV using Adobe® Photoshop to Obtain LV/RV Area 
 
Figure 9 Representation of Photoshop® Enhanced Image 
to Obtain Total Heart Area 
LV, RV and Total heart size were acquired for each image by creating a pixel to mm 
conversion factor (CF) using Microsoft® Paint, version 5.1 (Redmond, WA).  A straight 
line was drawn from the center of a millimeter marking on the ruler to the adjacent 
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marking and the length in pixels was recorded.  Finally, areas in mm2 [for each LV, RV, 
and total heart area) were calculated by dividing each section area (in pixels) by CF 
squared. 
Echocardiogram Methods 
Transthoracic Echocardiogram Method 
Two-dimensional echocardiography was used to measure the left ventricular 
structure and function two, four, and 10 weeks after the sarin injections.  Mice were 
anesthetized with 2% isoflurane in pure oxygen (five liters per minute) in an anesthesia 
chamber and maintained with 1% isoflurane by nose cone.  A Surgivet Anesco® Isotec 
4™ (Waukesha, WI) anesthesia machine was used to administer the isoflurane and 
oxygen.  Mice were then weighed using a Denver Instruments® XP-500 electronic scale 
(Denver, CO).  Once weighed, the mice were transferred to a heating pad and placed in 
a supine position.  The precordium was de-haired using the commercial product Nair® 
and an isopropyl alcohol pad (see Figure 10 and Figure 11).  
 
Figure 10 Mouse Anesthesia Procedure 
 
Figure 11 Mouse Being De-haired in the Precordium 
 
Echocardiograms were recorded using a Seimens® ACUSON Sequoia 512 
ultrasound system (New York, NY) with an ACUSON 15 megahertz transducer (model 
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15L8).  The transducer was coated with pre-warmed ultrasound transmission gel 
(Aquasonic™ 100 from Parker Laboratories, Inc., Fairfield, NJ).  Transthoracic two-
dimensional guided M-mode (2-D M-mode) and two-dimensional images were obtained 
via the parasternal apical windows (see Figure 12).  
 
Figure 12 Representative Echocardiogram Technique 
Three-second axis cine loops of the left ventricle (LV) were obtained in 2-D mode using 
the clip store function on the machine.  In addition, guided M-mode long axis LV, and 
pulsed wave Doppler images of the left ventricle were collected.  In weeks two and four, 
the mice were injected with dobutamine and the above procedure was repeated five 
minutes following the dobutamine injection.  (Five minutes was chosen to ensure that 
dobutamine had reached its onset of action; changes from the dobutamine were 
visually and acoustically obvious in the Doppler after one to two minutes, and Plante et 
al. have shown significant changes in a rat as soon as four minutes following a 
dobutamine injection (Plante, Lachance, Drolet, Roussel, Couet, & Arsenault, 2005)).  In 
week 10, ECG analysis (see the ECG Methods section) took place before the post 
dobutamine echocardiogram images were obtained from the mouse.  The mice were 
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injected with one milligram of dobutamine (in a saline solution) per kilogram of body 
weight (1 mg/kg).  This injection was made intraperitoneally (see Figure 13).   
 
Figure 13 Method of Dobutamine Injection 
Echocardiography Analysis Method 
Analysis was performed by a single observer using the Siemens® ACUSON 
Sequoia machine’s off-line analysis module.  (A separate observer (inter-observer) also 
analyzed a random sampling of the controls and sarin groups at varying weeks to ensure 
data quality; inter-observer results did not vary significantly from the single observer).  
Diastolic and systolic areas were measured via frame-by-frame analysis of the 2-D cine 
loops.  The inner edge of the ventricular endocardial border including the papillary 
muscle was measured for three consecutive sinus beats.  These values were recorded 
and averaged.  End diastolic area (EDA) measurements were made at the time of the 
perceptible maximal LV diastolic breadth, and end-systole (for end systolic area (ESA) 
measurements) was measured in the frame before ventricular expansion (see Figure 
14).  Ventricular septal wall thickness (SWT), posterior wall thickness (PWT), end 
diastolic diameter (EDD), and end systolic diameter (ESD) were made in accordance with 
the leading edge method from the 2-D M-mode images of the LV in both systole and 
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diastole as presented by the American Society of Echocardiography (Sahn, DeMaria, 
Kisslo, & Weyman, 1978) (see Figure 15).  Three separate measurements were made for 
each (SWT, PWT, etc.) and the values were recorded and averaged. 
 
Figure 14 Representative Area Measurement Method 
for 2-D Echocardiograms 
 
Figure 15 Representative Measurement Methods for 2-D 
M-mode Echocardiograms 
 Pulsed wave Doppler (see Figure 16) was used to measure B (iso-volumetric 
contraction time (ICT) plus iso-volumetric relaxation time (IVRT)), A (Ejection Time (ET)), 
aortic output velocity/time index (Ao VTI), and aortic output maximum velocity (Ao Vmax) 
(see Figure 17) in accordance with the previously described methods in the literature 
(Tei, Nishimura, Seward, & Tajik, 1997; Morgan, et al., 2004).  Three separate 
measurements (using a single observer) for each image were recorded and averaged.  
 
Figure 16 Example Pulsed Wave Doppler Image Showing 
Eight Full Sinus Rhythms 
 
Figure 17  Pulsed Wave Doppler Method of 
Quantification 
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Fractional shortening (FS), relative wall thickness (RWT), area fraction shortening (aFS), 
and the myocardial performance index were calculated using Equation 1, Equation 2, 
Equation 3, and Equation 4 (Morgan, et al., 2004; Syed, Diwan, & Hahn, 2005). 
Equation 1 Fractional Shortening Derived from M-mode Echocardiogram Images 
                                                                                                          (1) 
 
Equation 2 Relative Wall Thickness Derived from M-mode Echocardiogram Images 
                                                                                                  (2) 
 
Equation 3 Area Fractional Shortening Derived from 2-D Echocardiogram Images 
                                                                                                          (3) 
 
Equation 4 MPI Derived from Pulse Wave Doppler 
                                                                                                                        (4) 
(Where A and B are derived as per Figure 17). 
Finally, the derived parameters from the 2-D geometric and Doppler temporal data 
aFS/MPI and the mean circumferential fiber shortening velocity (Vcf) were calculated.  
Vcf was calculated using modified formulas presented by Broberg et al. (Broberg, et al., 
2003). 
Equation 5 Vcf derived from 2-D mode and Pulse Wave Doppler Echocardiograms 
                                                                                                                               (5) 
(Where B is derived as per Figure 17) 
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ECG Methods 
Telemetry Collection Procedure 
 ECG tracings were collected on the mice in conjunction with the 10 week 
echocardiograms.  The shaved area of the anesthetized mice was cleaned with an 
isopropyl alcohol pad and a two-lead telemetry probe, Data Sciences International (DSI) 
(St. Paul, MN) radiotelemetry probe model # TA11ETA-F10 (manufactured 15 May 
2009), was externally attached to the shaved precordium.  The upper right electrode 
was clipped just below the neck line in the dorsal thoracic region (near the front right 
limb); the lower left electrode was placed within the muscle tissue in the lower left 
abdominal wall, cranial to the groin area (see Figure 18).  
 
Figure 18 ECG Electrode Placements and Technique of Attachment 
The electrodes were clipped using a Schwartz micro-serrefine clip, and the 
transmitting end of the probe was placed over a DSI PhysioTel® receiver.  The heating 
pad had to be turned off during the ECG recordings (approximately 15 minutes) because 
the radio frequency generated by the induction coils interfered with the probe’s 
communication to the PhysioTel® receiver. 
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Telemetry was recorded using DSI’s Dataquest A.R.T.™ (version 4.0) acquisition 
software.  The manufacture’s probe calibration information was entered into the 
program and the program was set to record in ECG mode with a sampling frequency of 
5,000 hertz.  Tracings were recorded for approximately five minutes.  The mice were 
then injected with 1 mg/kg of dobutamine as described in the Echocardiogram Methods 
of this report.  Using the Dataquest® software, a mark was added to the ECG trace to 
indicate that the drug had been administered at that time.  The ECG tracings were 
recorded for an additional seven minutes after the dobutamine injection; this was done 
to ensure that ECG recordings were captured after the dobutamine took effect.  This 
effect was visually obvious from the real time ECG trace and usually took between two 
and three minutes. 
ECG Analysis Method 
The ECG tracings were analyzed using DSI’s Ponemah™ software (version 4.90).  
The A.R.T.™ files were imported into the Ponemah™ Physiological Platform and the 
software was set to record all available derived parameters under the channel input tab.  
Thirty seconds of the ECG tracings from before the dobutamine injection and 30 
seconds from after the dobutamine injection were analyzed for each mouse.  The 
Ponemah™ software’s analysis tool was used to automatically detect and mark the P, Q, 
R, S and T-waves.  The software was set to display all marks and all values in the std. 
attributes tab were set to the software’s predetermined values for a mouse (with the 
exception of the QT interval which was set to 70 milliseconds (ms) rather than 100 ms 
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because at 100 ms the QT interval overlapped the PR interval and the software would 
not recognize the P-wave if the intervals overlap).  Because the software had limited 
ability to detect all the P and T-waves, the software’s template analysis toolkit was also 
used.  One representative beat (P-start to T-end) was chosen and added to the template 
and the software was set to match all waves that matched the beat within 80% of the 
representative beat.  The peak of the T-wave was defined as the lowest point on the T-
wave after the end of the S-wave, and the end of the T-wave was placed where the T-
wave crossed the apparent iso-electric line (where the ECG became parallel to the x-
axis).  A representative ECG trace is depicted in Figure 19 and wave placement marks 
are depicted in Figure 20.   
 
Figure 19 Representative ECG Tracing 
 
Figure 20 Representative ECG Trace with Software 
Markings 
If the end of the T-wave encroached on the beginning of the P-wave (i.e. the T-wave 
does not return to the iso-electric level before the start of the P-wave), the end of the T-
wave was defined as the point just before the start of the P-wave (Figure 21).  Finally, 
the ECG trace was analyzed beat by beat by a single observer on separate days for each 
30 second interval; if the ECG trace showed an aberration (e.g. due to a respiration), the 
P-wave start
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Q-wave peak
R-wave peak
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S-wave end
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marks for the entire beat were excluded (see Figure 22); any missing marks from beats 
without aberration were added. 
 
Figure 21 ECG Trace Showing End of T-wave 
Encroachment on the P-wave Start 
 
Figure 22 ECG Trace with an Indiscernible T-wave Due to 
a Respiration 
The Derived data from the Ponemah™ program was then saved as a Microsoft® 
Excel™ file.  The Ponemah™ derived RR intervals (giving heart rate) were corrected to 
compensate for the deleted beats (indiscernible beats described previously); for 
example, intervals that had one deleted beat (Ponemah™ calculates RR as the interval 
from one marked R-wave to the next marked R-wave; the software is unaware if an 
intervening mark has been deleted) were divided by two.  In addition, a new QT 
corrected (QTC) interval was calculated using modified Bazett’s method (Bazett, 1920) 
from the corrected RR interval and the Ponemah™ derived QT interval.  Mitchell et al. 
have shown that the high resting heart rate of the mouse requires normalization of the 
RR interval to 100 beats per minute (Mitchell, Jeron, & Koren, 1998) 
Equation 6 Bazett/Mitchell QT Correction 
                                                                                                                  (6) 
 
P-wave start
T-wave end
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 To check for ST-T abnormalities using the Ponemah™ software, a novel method 
was developed.  Mitchell et al. and others (Mitchell, Jeron, & Koren, 1998; Kramer, van 
Acker, Voss, Grimbergen, van der Vijgh, & Blast, 1993; London, 2001), have shown that 
with respect to the QT segment the electrocardiogram of an adult mouse differs 
considerably from that of humans; notably the absence of an identifiable ST segment.  
Mitchell et al. note that there is an early-peaking, upright T-wave (with a broad inverted 
tale) that is merged with the end QRS.  In order to measure the ST segments and/or 
depressions/elevations van Acker et al. and others have used the interval from end of S 
to the T-peak (Nossuli, Lakshminarayanan, Baumgarten, G. E. Taffet, Michael, & Entman, 
2000; van Acker, Kramer, Grimbergen, van der Vijgh, & Blast, 1996).  (The Ponemah™ 
program’s ST-I parameter measures the ST interval from the S-peak to the T-end; not 
from the S-end, the parameter of interest to show ST elevation/depression).  
Accordingly, the following formulae were developed to define ST-T deviations: 
Equation 7 Corrected ST Segment Length 
                                                                                                                          (7) 
 
Equation 8 Corrected Length of T-peak to End of T 
                                                                     (See Figure 23)                               (8) 
 
QATN is defined as the distance from Q (in milliseconds) to the maximal deviation from 
the iso-electric line between the end of S and end of T.  QATN was used in place of Tpe-I 
because QATN is defined by the Ponemah™ software and less subject to human error 
(Tpe-I is placed by the observer where they believe the maximum deflection occurs).  
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Finally, the data from the 30-second analysis was averaged (QRS, QT, T-peak to T-end 
interval (Tpe-I), QATN interval, TC, and STC) for statistical analysis.   
 
Figure 23 ECG Trace Demonstrating ST and T Calculations 
 
Note that peak heights (such as T-peak measured as the deviation from the iso-electric 
line)  may seem to be a viable way of measuring ST depression, peak height (commonly 
used in 12-lead ECG) is dependent on electrode placement and QRS right/left axis shift 
and is not normally used in 2-lead telemetric ECGs. (Kramer, Kinter, Brockway, Voss, 
Remie, & Van Zutphen, 2001; Conover, 2003). 
ANP and BNP Methods 
Method of ANP and BNP Staining 
 Slides containing five-micron sections of the fixed heart tissue were de-
paraffined.  The sections were washed in a phosphate buffered saline (PBS) solution, 
subjected to 0.15% hydrogen peroxide for 15 minutes, and rewashed.  Sections were 
then blocked (with a normal goat serum (NSG) blocking solution) for one hour.  After 
blocking, the sections were rewashed and the primary antibody with dilution ratio was 
1/500 for BNP and 1/1000 for ANP antibody.  The primary ANP antibody was 
rabbit/anti-mouse and the primary BNP antibody was rabbit/anti-rat; both antibodies 
QATN
TC
STC
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were obtained from Bachem AG (Torrance, CA).  The sections were allowed to incubate 
for 24 hours prior to addition of secondary antibody.  The secondary ANP and BNP 
antibody was goat/anti-rabbit, and the dilution ratio for the BNP antibody was 1/400, 
and a 1/1000 dilution ratio was used for the ANP antibody.  After a one hour incubation 
the sections were stained with an Elite® Vectastain™ ABC stain kit (rabbit Immoglobulin 
(IgG), catalogue number EK6101) in conjunction with 3-3’-Diaminobenzidine 
tetrahydrochloride (DAB) tablets.  Finally, the slides were dehydrated and cleaned (with 
ethanol and xylene, respectively) and permount was used to bind a cover slip.   
ANP and BNP Quantification 
 Both BNP and ANP were quantified using the same method.  Pictures were taken 
at 5X magnification of the heart sections using a Leica Microsystems® (Bannockburn, IL) 
DMR microscope (type: 020-526-731) with a Optronics® (Goletta, CA) QuantFIRE® XI 
/MacroFIRE® 2.3A camera attached.  Optronics® PictureFrame™ imaging software was 
used to acquire the images.  A control group heart section was used to calibrate the 
light intensity, microscope settings, and camera settings.  The white balance was 
adjusted using the software’s ROI white balancing tool.  Once the light intensity, 
microscope, and camera settings were selected, they remained unchanged.  A single 
observer collected all the BNP photographs, and all images were collected using the 
same lighting and settings (ANP images were collected on a different day using the same 
procedures).  Approximately five to six images were collected for each heart section.  
These images were taken around the heart section in a manner that consummated the 
whole section when the images are merged (see Figure 24, Figure 25, and Figure 27). 
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A single observer used Molecular Devices®’ (Sunnydale, CA) software package 
Metamorph® (version 7.6) to perform the analysis of the images.  Uneven intensity of 
the 5X images was corrected using the software’s Background and Shading Correction 
function.  A blank slide was used to create two standard backgrounds (one background 
with the microscope’s light turned off and one background with the light at the same 
intensity that was used to photograph the sections) that were used to correct each 
photograph prior to analysis.  Figure 24 and Figure 25 show the difference of before and 
after the background correction.  (This step ensured that software’s color/intensity 
threshold selection tool would evenly select the staining regardless of its location on the 
slide).   
 
Figure 24 5X Magnification Photograph of  a BNP 
Stained Heart Section before Background Correction 
 
Figure 25 5X Magnification Photograph of  a BNP 
Stained Heart Section after Background Correction 
Using the control mice and the software’s Color/intensity threshold selection tool, a 
threshold was chosen (a priori of the sarin mice) for the BNP/ANP stain.  Figure 26 
demonstrates the selectivity of BNP/ANP using the threshold tool.   
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Figure 26 Representation of BNP/ANP Selection via Threshold Selection 
Because the threshold selection tool could not distinguish between unstained 
heart tissue and the slide background, it was impossible to measure the unstained tissue 
directly.  (Selecting the slide background would bias the results and artificially show 
increased BNP/ANP in the sarin mice since the ventricle space would be selected and 
the control mice showed significantly larger LV and RV space that the sarin mice; see 
section IV. Results and Analysis of this report).  Therefore, representative regions of a 
known pixel area were used.  Circular regions were selected to ensure that the heart 
section’s orientation on the slide did not affect the results.  Using the Metamorph® 
software all 5X images of a single heart were analyzed simultaneously such that five 
regions could be placed equidistantly in the left ventricle wall, and three regions in the 
septal wall and right ventricle wall.  Figure 27 (a composite of the 5X images to show the 
whole) is representative of the regions placement.   
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Figure 27 Whole Heart Section Composite of 5X Magnification Images with Representative of Region Placement in a 
BNP Stained Heart 
Finally, the Show Regional Statistics tool set was set to the Active Region setting 
and the data was logged to a Microsoft® Excel™ spreadsheet for each heart section.  LV, 
RV, and septum measurements were averaged, total ventricular ANP/BNP percentage 
was calculated as an average of the LV and septum measurements, and total percentage 
was calculated as a composite average of all three areas. 
Cell Size Quantification using an H&E Stain Method 
H&E Method of Staining 
 Paraffin was removed from the slides containing 5 micron thick sections of the 
fixed heart tissue.  The sections were washed, and then submerged in a Gill II 
hematoxylin solution for 30 seconds.  Finally, they were rinsed with water for 5 to 10 
minutes.  Ensuing hematoxylin, the sections were dehydrated (with xylene) and cover 
slipped with permount. 
Cell Size Quantification 
Pictures were taken at 20X magnification of the heart sections using the Leica 
Microsystems® DMR microscope (see ANP and BNP Quantification section of this 
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report).  The light intensity, microscope settings, and camera settings were setup as 
previously described and a single observer collected same day images using the same 
lighting and settings.  Three (separate and random locations) images of the 
cardiomyocytes were taken in the LV wall and one image was taken in the septum (The 
H&E images were taken in gray scale; a posteriori analysis revealed that the software 
program could better distinguish the nucleus from the cell tissue, see Figure 28). 
 
Figure 28 20X Magnification Picture of Gray Scale Image Showing H&E Staining of Cardiomyocytes in the Septum 
As with the BNP/ANP quantification, a single observer used Metamorph® to 
perform the analysis of the H&E images and the background shading was corrected as 
previously described (see ANP and BNP Quantification).  Two thresholds were created 
(same procedure as ANP/BNP): one threshold calibrated to select the nucleus and the 
second was calibrated to select the cell tissue.  The nuclei were counted using the 
Threshold selection tool in combination with the Integrated Morphometry Analysis 
(IMA) toolkit.  In the IMA toolkit, the Area filter was selected (to only select objects 30 
to 300 pixels; size selected by measuring several nuclei in the control mice), and the 
Shape filter was selected to only capture objects with circularity between 0.5 – 1.  Then 
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the total number of objects selected (as opposed to pixel count) was exported to Excel™ 
using the Object tab in the IMA toolkit.  Total cell area was selected using the Threshold 
selection tool and the total number of pixels selected was exported to Excel™.  As with 
the ANP/BNP, quantification settings (threshold, IMA, etc) were not changed 
throughout the analysis.  Figure 29 demonstrates the software’s ability to select nuclei 
(in green) and Figure 30 demonstrates the total tissue selection.   
 
Figure 29 20X Magnification H&E Picture w/Magnified 
Cut-out with Nuclei Selected using Metamorph's IMA 
toolkit  
 
Figure 30 20X Magnification H&E Picture with Total 
Tissue Selected using Metamorph's Threshold Tool 
 
Cell size was computed as total tissue area (pixels) per nucleus (number of objects 
selected using the IMA toolkit).  LV measurements were averaged and total average cell 
size was computed as an average of the LV measurements and the Septum 
measurement. 
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Picrosirius Red Staining Methods 
Method of Picrosirius Red Staining 
 Slides containing five-micron sections of the fixed heart tissue were de-
paraffined and washed in PBS.  The slides were then soaked in a Weigert’s iron 
hematoxylin stain kit (ENG Scientific, Inc., East Clifton, N.J) for eight minutes.  The slides 
were washed again.  Following the second wash, the slides were stained in a picrosirius 
red solution containing five grams of Direct Red 80 (Sigma-Aldrich Manufacturing, LLC, 
Lanexa, KA) and 500 ml of picric acid for 1 hour.  Then the slides were washed with 
acidified water and dehydrated with ethanol.  Finally, the slides were cleaned with 
xylene and covered with a permount bound cover-slip. 
Picrosirius Red Quantification 
 Pictures were taken at 5X magnification of the heart sections using an Olympus® 
FluoView™ FV300 Tissue Culture Microscope (Waltham, MA).  The FluoView™ 
application software was used to acquire the images.  An external polarizing light 
transmitter was used via the instrument’s external port.  A section of a control group 
heart was used to calibrate the light intensity and plane of polarization (crossed 
polarized at ~90 degrees), microscope settings, and camera settings.  Once the 
polarization, light intensity, microscope, and camera settings were selected, they were 
not changed.  A single observer collected all the photographs, and all images were 
collected using the same lighting and settings.  Approximately five to six images were 
collected for each heart section.  These images were taken around the heart section in a 
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manner that consummated the whole section when the images are merged (see Figure 
31 andFigure 32). 
 
Figure 31 5X Magnification Photograph of a Picrosirius 
Red Stained Heart Section in Crossed Polarized Light.   
The collagen transmits red light while the picric acid 
stained tissue appears black. 
 
Figure 32 Photoshop® Enhanced Image of a Sirius Red 
Stained Heart Image Showing the Total Heart Area. 
 
A single blinded observer used Adobe® Photoshop® CS3 (version 10.0.1), to 
perform the analysis of the images.  The 5X images were copied on to a transparent 
background and merged using Photoshop’s® Auto-Align Layers tool.  The images were 
checked to ensure quality, and a preselected color range was used to quantify the sirius 
red staining from the dark image.  This was accomplished using the Color Range toolset 
under the Select menu in Photoshop®.  The preselected color range was not changed 
during the analysis and the same color range was used for all the images.  The 
Histogram tool was used to record the total number of pixels selected for the sirius red 
stain. 
Total heart section size (in pixels) was calculated in a similar manner as was used 
in the heart size quantification explained above (see the Tissue Collection, Heart 
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Sectioning, and Heart Size Measurement Methods/Heart Section Size Measurements 
section of this report).  The image was enhanced using the software’s Adjustments 
toolset to increase the brightness of the image (all images were increased by the same 
brightness level) (see Figure 32).  The RV and LV were the manually cropped from the 
heart sections using the Quick selection and Magic wand tool sets (see Figure 33).  After 
the ventricles were cropped, the heart section was selected (using the Quick 
selection/Magic wand tools as described above) and pasted into a blank image with 
transparent pixels; the histogram tool was used to calculate the total heart area. 
 
Figure 33 Representation of Photoshop® 
Enhanced Sirius Red Stained Heart Image to 
Obtain Total Heart Area 
Finally, collagen levels were expressed as the ratio of the Sirius red stained pixels to the 
number of pixels in the total heart area. 
Statistical Methods 
Statistical analysis of the mice was performed using Prism 5® for Windows® 
(GraphPAD Software, Inc., La Jolla CA; version 5.01).  In general, one-way Analysis of 
Variance (ANOVA) with Nueman-Keuls post-hoc test was used to compare the controls 
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to the 0.4 LD50 and 0.5 LD50 groups.  Any significant results were checked for equal 
variances and normality; Batlett’s test for equal variances (p < 0.05), and D'Agostino-
Pearson’s omnibus test (p < 0.5) or the Shapiro-Wilks’ (p < 0.5) normality test (if the 
sample size was small, i.e. n = 5 for the 0.5 LD50 group) were used, respectively.  
(Corrective methods used to compensate for failure of either test are given below).  Any 
data that failed the normality tests were analyzed using Kruskal-Wallis’ test with Dunn’s 
post-hoc test. 
In the case where data collection was repeated on multiple different weeks 
(body weights, echocardiography, etc), the mice were time-matched.  One-way ANOVA 
was performed with the controls versus each sarin group (0.4 LD50 and 0.5 LD50) for each 
time-matched group (week 2 results, week 4 results, etc) with Nueman-Keuls post-hoc 
test.  Additionally, two-way ANOVA (time-matched group x dobutamine) with a 
Bonferonni post-hoc test was performed on the time-matched data on any significant 
results (from the one-way ANOVA) in the ECG and echocardiograms where dobutamine 
was used.   
Finally, when only two groups were analyzed (the sarin groups were combined 
and pitted against the controls) a Student’s t-test was used.  Results were checked for 
normality (D'Agostino-Pearson, p < 0.5), and equal variances (Bartlett’s test).  Kruskal-
Wallis with a Dunn’s post-hoc test was used if the data did pass the normality tests. 
Welch’s correction for unequal variances was used if variances were not equal or could 
not be assumed (p < 0.25). 
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IV. Results and Analysis 
Results of Body Weights, Tissue and Heart Sectioning Weights 
 Time-matched, one-way ANOVA on body weight shows a significant decrease in 
body weight of the sarin mice versus the control group after the sarin injections.  By 
week 10 the differences in weights were no longer significant.  ANOVA on weight gain 
percentages shows a significant decrease in body weight for the 0.5 LD50 group.  By 
week four, weight gains leveled and no significant weight loss/gains were observed for 
the duration of the experiment (see Figure 35).  See Appendix A: Tabulated Average 
Results of Controls, 0.4 LD50, and 0.5 LD50 Groups/Tabulated Results of Weights and 
Heart Section Measurements for a complete list of body weights at the given time-
intervals. 
 
Figure 34 Results of Murine Body Weights. 
Body Weight shows a significant decline in weight 24 
hours post exposure and remains Low for the remainder 
of the experiment; although, not significantly lower in 
week 10. 
 
Figure 35 Results of Percent Change in Body Weight. 
Percent change in body weight shows a significant 
decline in weight 24 hours post exposure for the 0.5 
LD50 group.  By the 4th week change in body weights 
leveled, and by experiment end weight changes were 
nearly Identical for each group. 
Results of Body Weights, Tissue Weights, and Heart Sectioning  
ANOVA of the corrected heart weights (time-matched heart weight/body 
weight) did not show a significant difference between the two sarin groups and the 
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control group (see Figure 36).  The data, however, showed a trend for increased heart 
weights in both sarin groups (f-statistic = 2.9, p = 0.07).  In order to gain statistical power 
(and reduce the error associated with the 0.5 group, n =5), the two sarin groups were 
combined, and compared against the controls using Student’s t-test with Welch’s 
correction for unequal variances.  Results indicate that corrected heart weights were 
increased (p = 0.026) in the mice subjected to sarin (see Figure 37). 
 
Figure 36 Results of Heart Weights (Corrected by Body 
Weight). 
Results lack statistical power to show a significant 
difference (p = 0.07).  Corrected heart weights for both 
sarin groups show an increasing trend in weights. 
 
Figure 37 Results of Corrected Heart Weights with 
Combined Sarin Groups. 
With the two sarin groups (0.4 LD50 and 0.5 LD50) 
combined, results of heart weights (corrected by body 
weight) show a significant difference (p = 0.026).  
Corrected heart weights for the sarin groups show 
increased corrected heart weight. 
Similarly, an unpublished study by this lab showed significant increased corrected heart 
weight values (Morris, Lucot, & Shewale, 2009) eight weeks after exposure (see 
Appendix B: Unpublished Heart Weight Data  
The three-millimeter heart sections showed a significant decrease in LV lumen 
area for both sarin groups.  Figure 38 shows a normal heart section of a control mouse 
and Figure 39 demonstrates decreased ventricular area in the sarin subjected mice. 
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Figure 38 Representative 3mm Section of Control 
Mouse Showing Normal Ventricular Size 
 
Figure 39 Representative 3mm Section of 0.4 LD50 Group 
Showing Severely Depressed Ventricular Areas 
 ANOVA on the three-millimeter heart section pictures show a significant decrease (p = 
0.0014) in LV area for both the 0.4 LD50 and 0.5 LD50 sarin groups.  Although not 
significantly, the RV area also appeared depressed and the total heart area increased.   
 
Figure 40 Results of Ventricular Size. 
Results show a significant decrease (p = 0.0014) in LV area for 
both groups of sarin mice. 
Tabulated results showing average values (± standard error) for the controls and sarin 
groups for the body weights, heart weights, and heart sizes are listed in Appendix A: 
Tabulated Average Results of Controls, 0.4 LD50, and 0.5 LD50 Groups/Tabulated Results 
of Weights and Heart Section Measurements. 
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Results of Echocardiography Analysis 
 2-D echocardiograms show significant size increases in the ESA and EDA of both 
sarin groups versus the controls (time-matched one-way ANOVA).  Both groups showed 
a significant increase in ESA by week 4, and the 0.5 LD50 group also had a significantly 
increased EDA in week 4; the 0.4 LD50 did not show significant results in EDA until week 
10.  By week 10, size differences in the 0.5 LD50 group seemed to have reverted and 
differences were no longer apparent.  Dobutamine significantly increased cardiac output 
and seemed to mute the differences between groups.  After dobutamine 
administration, only the ESA in the week 4 of the 0.5 LD50 group showed variation from 
the controls (see Figure 41 and Figure 42).   
 
Figure 41 Results of Echocardiogram ESA. 
Week 4 ESA (cm2) was significantly increased in the sarin 
groups before dobutamine, and in the 0.5 LD50 group 
after dobutamine.  Week 10 results show further 
increase in area in the 0.4 LD50 group, While the 0.5 LD50 
group matched the controls. Two-way ANOVA (controls x 
0.4 x 0.5 LD50 groups) did not show a significant 
difference in the interaction (dobutamine had the same 
effect on each group).   
 
Figure 42 Results of Echocardiogram EDA. 
Week 4 EDA (cm2) was significantly increased in the 0.5 
LD50 group before dobutamine.  Week 10 results show an 
increased EDA in the 0.4 LD50 group, While the 0.5 LD50 
group matched the controls.  Two-way ANOVA (controls x 
0.4 x 0.5 LD50 groups) did not show a significant 
difference in the interaction.  
Two-way ANOVA of the week 4 ESA showed significant differences between the 
controls and sarin (p = 0.0005) and for all groups before and after dobutamine (p < 
0.0001), but did not give a significant interaction (p = 0.24) – dobutamine affected each 
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group equally.  Week 10 two-way ANOVA of the ESA gave similar results to the week 4 
data; significant differences between groups (p = 0.014) and pre/post dobutamine effect 
(p < 0.0001), but not a significant interaction (p = 0.20).  Two-way ANOVA on EDA in 
both week 4 and week 10 gave similar results to that of the ESA analysis (significant 
difference between groups and pre/post dobutamine, and no significance in the 
interaction). 
 Area fractional shortening (aFS) is a dependent of ESA and EDA (aFS = [EDA – 
ESA]/EDA) and showed a similar pattern of results as the latter parameters.  Both the 
0.4 and 0.5 LD50 groups showed decreased aFS in week 4 before dobutamine, but the 
results were not significant (f-statistic = 3.039, p = 0.065).  By week 10, the 0.4 LD50 
group demonstrated a significant decrease in aFS (see Figure 43).  As with the ESA and 
EDA parameters, dobutamine muted the differences between controls and the sarin 
groups.  No significant values were obtained in aFS following the dobutamine injection.   
 
Figure 43 Results of Echocardiogram aFS. 
Week 4 aFS was depressed in the sarin groups, but not 
significantly (f = 3.039, p = 0.065).  Week 10 aFS was significantly 
decreased in the 0.4 LD50 group before dobutamine.  Two-way 
ANOVA (controls x 0.4 x 0.5 LD50 groups) did not show a 
significant difference in the interaction. 
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Two-way ANOVA on week 10 aFS gave similar results as the ESA and EDA analysis.  
Difference between groups was significant (p = 0.02), the dobutamine had a significant 
effect (p < 0.0001), and the interaction was not significant (p = 0.69). 
 Pulsed wave Doppler imaging showed significant results in week 10 for the ET 
interval after dobutamine in the 0.5 LD50 group (p = 0.0079).  Additionally, the ICT + IVRT 
interval was increased after dobutamine administration in both sarin groups (p = 
0.0097).  Two-way ANOVA expressed significant differences in between-group and 
pre/post dobutamine effects for ET and ICT + IVRT, but did not show any differences in 
the interaction for either parameter. 
 
Figure 44 Results Doppler Derived ET. 
In week 10 ET was increased in the 0.5 LD50 group (p = 
0.0079) following dobutamine.  Two-way ANOVA 
(controls x 0.4 x 0.5 LD50 groups) did not show a 
significant difference in the interaction.   
 
 
Figure 45 Results Doppler Derived ICT + IVRT. 
Week 10 ICT + IVRT was increased in both sarin groups (p 
= 0.0097) following dobutamine.  Two-way ANOVA 
(controls x 0.4 x 0.5 LD50 groups) did not show a significant 
difference in the interaction. 
Time matched one-way ANOVA on the derived parameters from the combined 
2-D/ Doppler images gave significantly decreased indices in week 4 aFS/MPI before 
dobutamine in both sarin groups (p = 0.026), and the 0.4 LD50 group also showed a 
significant decrease in week a10 FS/MPI (p = 0.0023) versus the controls.  The Vcf index 
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was also decreased before the dobutamine administration in week 10 for the 0.4 LD50 
group (p = 0.0061). 
 
Figure 46 Results Echo/Doppler Derived aFS/MPI. 
Week 4 FS/MPI was significantly lower in the sarin 
groups before dobutamine.  FS/MPI in the 0.4 LD50 group 
was further decreased in week 10, and the 0.5 LD50 
group no longer showed a difference.  Two-way ANOVA 
(Controls x 0.4 x 0.5 LD50 Groups) did not show a 
significant difference for the interaction or group effect. 
 
Figure 47 Results Echo/Doppler Derived Vcf. 
Week 10 Vcf was significantly decreased in the sarin 
groups before dobutamine, and the 0.5 LD50 group was 
decreased but not significantly.  Two-way ANOVA 
(controls x 0.4 x 0.5 LD50 groups) did not show a 
significant difference for the interaction or group effect. 
Two-way ANOVA expressed a significant difference pre/post dobutamine for both 
parameters (all weeks), but did not show any differences between groups or in the 
interaction for either parameter.  Other 2-D, M-Mode, and Doppler derived parameters 
were not significant (to include the myocardial performance index (MPI)).  Tabulated 
results of all the echocardiograms are listed in Appendix A: Tabulated Average Results of 
Controls, 0.4 LD50, and 0.5 LD50 Groups/Tabulated Results of Echocardiograms. 
Results of the ECG Analysis 
 Results of quantifying the ECG tracings show STC depression following 
dobutamine stressing in the sarin mice.  Visual qualification of the ECG tracings gave 
evidence of ST depression in three of the eleven control mice and in all but two of the 
sarin mice (combined groups).  In the sarin groups, the J-point (upright t-wave with a 
broad inverted tail that is merged with the end of QRS as described by Mitchell et al. 
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(Mitchell, Jeron, & Koren, 1998)) was significantly depressed.  In both sarin groups, the 
t-wave was shifted toward QRS and lengthened.  Figure 48 – Figure 53 demonstrate the 
differences seen in the t-wave for the control mice versus the sarin mice.  
 
Figure 48 Control Mouse ECG Trace Before Dobutamine 
Injection.   
The J-point rises above the iso-electric point and the T-
wave tail falls below the iso-electric point before 
returning (marking the iso-electric relaxation time).  
Note: as depicted TC is not corrected by the (RR/100)
1/2. 
 
Figure 49 Control Mouse ECG Trace After Dobutamine 
Injection.   
The J-point rises above the iso-electric point.  The STC 
segment and TC segments do not change markedly.   
 
 
Figure 50 Sarin Mouse ECG Trace Before Dobutamine 
Injection.   
The J-point rises above the iso-electric point slightly less 
than the controls (but not markedly). 
 
Figure 51 Sarin Mouse ECG Trace After Dobutamine 
Injection Showing ST Depression.   
The J-point does not rise to the iso-electric point.  The 
STC segment is slightly shortened when compared to the 
controls and TC segment is significantly lengthened. 
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Figure 52 Sarin Mouse ECG Trace Before Dobutamine 
Injection. 
The ST is slightly depressed.  The T-wave tail falls below 
the iso-electric point before returning. 
 
Figure 53 Sarin Mouse ECG Trace After Dobutamine 
Injection Showing Severe ST Depression.   
The J-point does not rise to the iso-electric point.  The 
STC segment is significantly shortened when compared to 
the controls and TC segment is significantly lengthened. 
 One-way and two-ANOVA show significant shortening in the STC segment and a 
significant increase in TC.  (One control mouse was excluded from the STC and TC analysis 
due to the presence of inverted t-waves; inclusion in the analysis skews results to show 
an even greater difference between the controls and sarin groups).  Additionally, the PR 
interval showed a significant increase in the 0.5 LD50 sarin group after dobutamine in 
week 10 (see Figure 54, Figure 55, and Figure 56).  Two-way ANOVA (control group x 
either sarin group) did not show a difference in dobutamine effect for any of the 
significant parameters.  Two-way ANOVA (controls x 0.4 LD50 x 0.5 LD50) was also 
performed on heart rate, and the results did not show a significant difference in the 
dobutamine interaction of the groups (p = 0.33) or any other parameter (between 
groups or pre/post dobutamine).   
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Figure 54 Results of ST Segment Measurements.   
Results show a significant decrease in segment length in the 
sarin groups following the dobutamine injection.  Two-way 
ANOVA shows significant results for sarin groups vs. controls 
(p =0.0015) and for dobutamine effect (p < 0.0001), but do 
not show that dobutamine had a different affect on controls 
vs. sarin groups (p = 0.82). 
 
Figure 55 Results of T-Peak to T-End.   
Results show a significant alteration of the T-Wave in 
both sarin groups following the dobutamine injection. 
Two-way ANOVA shows significant results for sarin 
groups vs. controls (p =0.032) but not for dobutamine 
effect (p < 0.2) or that dobutamine had a different 
affect on controls vs. sarin groups (p = 0.16). 
 
 
Figure 56 Results of PR Interval.  
Measurements show a significant segment length increase in the 
0.5 LD50 group following the dobutamine injection (p = 0.0056). 
Two-way ANOVA did not show significant results.  Sarin groups 
vs. controls (p =0.11); dobutamine effect (p = 0.26); dobutamine 
had a different affect on controls vs. the sarin groups (p = 0.67). 
 
Other measured ECG parameters were not significant to include the QTC interval.  
Tabulated results of all measured ECG parameters are listed in Appendix A: Tabulated 
Average Results of Controls, 0.4 LD50, and 0.5 LD50 Groups/Tabulated Results of ECG 
Data Analysis. 
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Results of ANP/BNP Stain Quantification 
Both ANP and BNP levels in the sarin mice were elevated in the LVs and RVs.  
Figure 57 andFigure 58 show the differing levels of natriuretic peptides (BNP was similar 
to the ANP sections) in the control and sarin groups. 
 
Figure 57 5X Magnification Images of BNP Staining in 
the Control Group Representative BNP (and ANP) Stain 
Pattern for the Control Mice 
 
Figure 58 5X Magnification Images of BNP Staining in 
the 0.4 LD50 Sarin Group and Representative of the BNP 
(and ANP) Stain Pattern for both Sarin Groups.  
Sarin mice had a greater prominence of BNP (and ANP). 
 ANOVA results of the ANP staining show significant increases in ANP levels in the 0.4 
LD50 group.  The LV wall, septum, and total ANP levels in the LV (LV wall and septum) 
were significantly higher (see Figure 59).  While increased ANP levels were seen in the 
RV, the results were not significant.  (Results shown exclude one heart section from the 
0.4 LD50 group; visual analysis of the section did not show any indication of stain in the 
section, and the quantification gave results up to 4X the standard error below the 
lowest quantified result of any other section, regardless of group).  Because a similar 
trend was noticed between both sarin groups, a Student’s t-test was performed; 
controls x combined average of the two sarin groups.  Results of the t-test indicate that 
all sarin animals had a significant increase in ANP in LV wall (see Figure 60).   
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Figure 59 Unitless Representation of ANP 
Quantification.  
Results show a significant increase in LV ANP levels in the 
0.4 LD50 group (LV wall, septum, LV total (LV wall + 
septum)).  The 0.5 LD50 group failed to show significant 
Results, but demonstrated an increased trend in both 
ANP and BNP quantification (Figure 61). 
 
Figure 60 ANP Quantification With The Two Sarin 
Groups (0.4 LD50 and 0.5 LD50) Combined. 
Results of the combined ANP analysis shows a significant 
difference (p = 0.028) in ANP levels in the LV wall for the 
sarin mice. 
 
 BNP levels follow the ANP levels in showing an increased trend in the LV wall, 
septum, and total BNP levels in the LV.  However, BNP results were slightly less than 
significant (p = 0.07) when compared individually (see Figure 61).  To increase statistical 
power and because a similar trend was noticed between both sarin groups, a Student’s 
t-test was performed (controls by combined-average of the two sarin groups: Figure 62).  
As with the ANP levels, BNP levels were significantly (p = 0.01) higher in the LV wall.  
Additionally, total average BNP levels in the heart section (average LV wall, septum, and 
RV) were significantly higher in the sarin animals (p = 0.04).  Tabulated results of the 
ANP and BNP quantification are listed in Appendix A: Tabulated Average Results of 
Controls, 0.4 LD50, and 0.5 LD50 Groups/Tabulated Results of Histology: ANP/BNP 
Quantification. 
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Figure 61 Unitless Representation of BNP 
Quantification.  
Groups lack statistical power to show a significant 
deviation (p = 0.07), but follow the ANP level trends. 
 
Figure 62 BNP Quantification With The Two Sarin Groups 
Combined (0.4 LD50 and 0.5 LD50).  
Results of the combined BNP analysis shows a significant 
difference (p = 0.010) in BNP levels in the LV wall and in 
the total BNP percentage (p = 0.04) for the sarin mice.   
Results of Cardiomyocyte Size via H&E Analysis 
 Cardiomyocyte size in the sarin groups increased significantly when compared to 
the control mice.  Figure 63 depicts the typical myocyte arrangement in a control 
mouse; Figure 64 shows increased size and density of the myocytes in a sarin mouse.  
 
Figure 63 40X Magnification Image of the 
Cardiomyocytes in the LV Wall of an H&E Stained 
Control Mouse 
 
Figure 64 40X Magnification Image of the 
Cardiomyocytes in the LV Wall of an H&E Stained Sarin 
Mouse Showing Myocyte Enlargement and Expansion 
into the Intercellular Space 
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One-way ANOVA on the H&E did not show a significant difference between the 
two sarin groups and the controls (see Figure 65).  However, the data did show a trend 
in both sarin groups (f-statistic = 3.2, p = 0.06) of increased average cardiomyocytes size 
in the LV (LV wall and septum).  When the two sarin groups were combined and 
compared against the controls using Student’s t-test, cell size was significantly increased 
(p = 0.025) in the LV wall of the sarin mice.  Cell size was not shown to be different in 
the septum (see Figure 66). 
 
Figure 65 Results of H&E Analysis.   
Results lacked statistical power to show a significant 
difference (p = 0.07 for LV wall).  Analysis did show an 
increasing trend in cell size for both sarin groups. 
 
Figure 66 Results of Combined H&E Analysis.  
Combining the two sarin groups (0.4 LD50 and 0.5 
LD50), demonstrates increased cell size in the LV wall 
(p = 0.025) for the H&E analysis. 
 
Tabulated results of the cell size quantification (± standard error) are listed in Appendix 
A: Tabulated Average Results of Controls, 0.4 LD50, and 0.5 LD50 Groups/Tabulated 
Results of Cell Size Quantification from H&E Staining, Collagen Quantification from 
Picrosirius Red Staining.   
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Results of Collagen Quantification via Picrosirius Red Staining 
 Collagen quantification did not show significant differences between the sarin 
subjected mice and the controls.  Results for the collagen quantification are listed in 
Appendix A: Tabulated Average Results of Controls, 0.4 LD50, and 0.5 LD50 Groups/ 
Tabulated Results of Cell Size Quantification from H&E Staining, Collagen Quantification 
from Picrosirius Red Staining. 
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V. Discussion 
Body Weights, Tissue and Heart Sectioning Weights 
 Although body weight was suppressed in the sarin mice, percent weight gain did 
not show a significant difference after two weeks.  Weight gain depression was seen in 
the sarin mice 24 hours after exposure; the 0.5 LD50 group showed significant 
depression while for the 0.4 LD50 group the depression was less severe.  Weight losses 
leveled off by the fourth week (see Figure 35), and the pattern was consistent with the 
literature for nerve agent exposures in mice and other small mammals (Bide & Risk, 
2004; Grauer, et al., 2008; Shih, Hulet, & McDonough, 2006).  Nonetheless, by week four 
weight gains had leveled off, and no more significant results were noticed.  As such, the 
heart had 10 weeks to normalize to the changes in weight, and weight gain/loss is not 
expected to be a significant factor in this experiment.   
Signification of Histological Evidence  
 Figure 67 illustrates the histological evidence of sarin induced murine LV 
hypertrophy.  Heart tissue weight ratios (corrected by body weight) were significantly 
larger in the sarin mice.  In addition, there was significant reduction in LV lumen in both 
sarin groups as quantified from the three-millimeter heart section.  Both measures are 
suggestive of hypertrophy, and the heart sectioning specifies LV hypertrophy.   
Similarly, H&E staining reveals higher cross-sectional areas of the 
cardiomyocytes.  The role of cardiomyocytes in hypertrophic cardiomyopathy has been 
previously established in the literature (Takeda, et al., 2010; Harada, et al., 1997), and 
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the results of the H&E stain myocyte size quantification of cardiomyocyte size coincides 
with heart weight and sectioning data. 
 
Figure 67 Histology Showing LV Hypertrophy in Sarin Mice.   
The ratio of heart weight/body weight ratio (Hw/Bw) (mg/g) was evaluated and found significantly higher in the sarin 
mice.  Paraffin-sectioned LVs were stained with H&E and the cross-sectional areas of cardiomyocytes were 
significantly larger in the sarin animals.  ANP and BNP quantification found significantly higher in the LV of the sarin 
mice. 
Additionally, ventricular expression of ANP/BNP is up-regulated in the LV in a 
host of cardiac pathological conditions leading to cardiac remodeling such as LV 
hypertrophy (Yasuno, et al., 2009), and Harada et al. have shown that significantly 
higher ANP/BNP production in cardiomyocytes (and non-cardiomyocytes) accompanies 
hypertrophic conditions (Harada, et al., 1997).  Indeed, disruption of the ANP gene or 
knockout of the receptor, NPR1, in mice induces such remodeling (Lopez, et al., 1995; 
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Knowles, et al., 2001), and ANP when expressed in the ventricles serves a role as one of 
the most conservative markers of LV hypertrophy (Day, et al., 1987).  In addition, BNP is 
released by the ventricles and serves as a superior diagnostic marker for heart failure 
(Mair, 2008).  Therefore, the higher levels of ANP and BNP seen in the two sarin groups 
gives strong evidence of cardiac remodeling and LV hypertrophy.  Such results of 
corrected heart weights, section sizing, cardiomyocyte size, and ANP/BNP level 
increases have been reported in the literature for mice with LV hypertrophy (Honsho, et 
al., 2009; Galindo, et al., 2009; Takeda, et al., 2010). 
Collagen levels in the heart were not increased in either sarin group; increased 
collagen levels normally serve as an excellent indicator of decreased cardiac 
performance (Lutgens, Daemen, Muinck, Debets, Leenders, & Smits, 1999; Kerckhovena, 
Kalkmana, Saxenaa, & Schoemaker, 2000).  Nonetheless, the absence of increased 
collagen does not turn aside cardiac dysfunction; indeed remodeling and LV 
hypertrophy has been shown in mice without increased collagen formation (Holtwick, et 
al., 2003), and in gene knockout-mice (where the removal gene has been shown not to 
inhibit collagen levels) (Fedak, et al., 2010; Kassiri, et al., 2009). 
Electrocardiographs: Inference of Ventricular Performance and Hypertrophy 
Coinciding with the histology, the murine ECG data shows significant ST segment 
changes and ST depression in the dobutamine stress test; ST segment deviations are 
demonstrated in Figure 68.  Similar to humans, the ST segment in a mouse corresponds 
to the leveling in action potentials when the heart is depolarized; the T-wave 
corresponds to ventricular re-polarization (London, 2001).  As such, ST segment 
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deviations (depression, e.g.) are well-documented indicators of myocardial/sub-
endocardial ischemia in mice and humans (Tomai, Crea, Chiariello, & Gioffrè, 1999; 
Lambiase, Edwards, Cusack, Bucknall, Redwood, & Marber, 2003; Chu, Otero, Lopez, 
Morgan, Amende, & Hampton, 2001; Stoller, et al., 2007).   
 
Figure 68 ECG Showing ST Changes in Sarin mice.  
Results are indicative of myo/endocardial ischemia in sarin mice.  The STC segment was depressed in the sarin mice 
following dobutamine; T-Peak was shifted left and the TC interval lengthened.   
Additionally, dobutamine stress testing is a well documented test for ischemia 
(Shaheen, Luria, Klutstein, Rosenmann, & Tzivoni, 1998), and ischemia has been 
associated with cardiac hypertrophy, because the coronary circulation system does not 
experience concomitant growth with the hypertrophic cardiac muscle (Smits & Smits, 
2004).  Accordingly, ST and T-wave changes represent decreased cardiac performance 
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under stress and ventricular strain patterns that could be associated with LV 
hypertrophy (Hsieh, Pham, & Froelicher, 2005).   
 Prolongation of the QTC interval has been reported in rat sarin studies (Abraham, 
Oz, Sahar, & Kadar, 2001) and organophosphate poisonings in humans (Roth, Zellinger, 
Arad, & Atsmon, 1993; Chuang, Jang, Lin, Chern, Chen, & Hsu, 1996), however, this 
study did not show changes in QTC interval.  It is unknown at this time why QTC 
prolongation was not seen in this study.  Allon et al. also report QTC interval changes in 
rats exposed to sarin, but the QTC interval change is only apparent in rats that received a 
high dose (convulsive) and only in the first two weeks post exposure.  After two weeks 
time (within four weeks after exposure), most of the animals’ QTC intervals had returned 
to the control level (Allon, Rabinovitz, Manistersky, Weissman, & Grauer, 2005).  
Because this study only collected ECG tracing in week 10, it is impossible to ascertain if 
no QTC prolongation or if QTC prolongation may have occurred earlier in the study as 
described by Allon et al.  Additionally, seven animals from the 0.5 LD50 group died, and it 
is possible that these animals may have had an increased QTC had they lived. 
Echocardiograms and Implication to Left Ventricular Performance 
 2-D echocardiography showed a significant decrease in LV performance and 
function in the sarin animals.  Sarin mice before dobutamine infusion showed 
significantly increased ventricular areas and decreased aFS in the later weeks of the 
study (weeks 4 and 10).  This data parallels a previous, unpublished study by this lab in 
which mice injected with sarin (64µg/kg) showed significant increases in ESA, EDA four 
and eight weeks (no changes at 2) following the exposure (Morris, Shewalel, Lucot, & 
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Izu, 2007) (although, this previous study did not use Doppler imaging).  In addition, in 
this study the combined 2-D and Doppler imaging parameters, aFS/MPI (weeks 4 and 
10) and Vcf (week 10), were significantly decreased before dobutamine (see Figure 69).   
 
Figure 69 Echocardiography Data Showing Decreased LV Performance in Sarin Mice.  
ESA was significantly increased in the sarin mice in week 4 and in the 0.4 LD50 group in week 10, and EDA was 
increased in the 0.5 and the 0.4 LD50 groups in weeks 4 and 10, respectively.  Performance parameters, aFS, aFS/MPI, 
and Vcf were also decreased significantly in weeks 4 and 10. 
aFS/MPI and Vcf serve as superior indicators of overall LV function since these values 
take into account both geometric and temporal measures of LV function (Broberg, et al., 
2003; Syed, Diwan, & Hahn, 2005), and these values compare to the traditional 2-D 
echocardiography parameter aFS.  Additionally, the ICT + IVRT and ET (0.5 after 
dobutamine) parameters were significantly lengthened after dobutamine.  Tei et al. 
have shown both parameters to correlate with LV function and dysfunction (Tei, 
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Nishimura, Seward, & Tajik, 1997), and both parameters have been shown as effective 
measures after dobutamine infusion (Norager, Husic, Moller, & Egstrup, 2004; Duncan, 
Francis, Henein, & Gibson, 2003).  While ICT + IVRT usually lengthens during LV 
dysfunction, longer ET intervals are usually associated with a healthy heart; 
nevertheless, ET lengthening has been shown to increase when hypertrophic 
cardiomyopathy is present (Hamada, et al., 2003; Nahrendorf, et al., 2006). 
ESA and EDA increases can serve as early indicators of cardiac pathology; 
whereas, decreased aFS is indicative of diminished cardiac performance (Syed, Diwan, & 
Hahn, 2005).  Increases in ESA and EDA seen in week 4 in the 0.5 LD50 group with 
reversion in week 10 could be an early onset of the pathology.  By week 4, the disease 
had progressed further in the 0.5 LD50 group as evident by the larger changes in the EDA 
and ESA than the 0.4 LD50 group in week 4.  The pathology causing the increased 
ESA/EDA induced the onset of remodeling (hypertrophy) earlier in the 0.5 LD50 group, 
and by week 10 the concentric hypertrophy (thus thickening of the LV walls) was more 
advanced in the 0.5 LD50 group.  Therefore, the week 10 echocardiograms of the 0.5 
LD50 group show correction as the remodeling thickened the muscle and reduced the 
ESAs and EDAs (often seen in later stages of concentric hypertrophy (Shub, 2008)).  
There is some evidence for this in the histology as well.  The 0.5 LD50 group showed a 
higher trend in corrected heart weight (Figure 36), decreased ventricular area and 
increased whole heart muscle area (Figure 40), and increased cell size (Figure 65) when 
compared to the 0.4 LD50 group; indicating an increased level of hypertrophy in the 0.5 
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LD50 group.  Additionally, the 0.4 LD50 group tended to have increased ANP (Figure 59) 
and BNP (Figure 61) levels when compared to the 0.5 LD50 group; indicating an increased 
level of ongoing remodeling in the 0.4 LD50 group.  Nevertheless, this study cannot 
prove this (additional weeks would be needed to observe whether or not the 0.4 LD50 
group eventually corrected to the control levels in echocardiography and ANP/BNP 
levels) and additional study is needed to provide further insight. 
 Finally, the results of the M-mode echocardiography did not correlate with the 2-
D results.  In addition, M-mode failed to show increased thickness of the SWT or PWT, 
and LV hypertrophy could not be confirmed by M-mode echocardiography.  In general, 
2-D echocardiography is a more robust technique of measuring the LV than M-mode 
(Prasad, Atherton, Smith, McKenna, Frenneaux, & Nihoyannopoulos, 1999; Shub, 2008).  
In M-mode only a plane of the LV is measured with a single ultrasound beam; whereas, 
2-D analysis allows for a more complete geometric description and spacial distribution 
of the LV.  Therefore, one possible explanation is that the remodeling (or hypertrophy) 
cannot be readily diagnosed in M-mode (but easily seen in the 2-D) due the location of 
the cardiomyopathy in the LV (Maron, Gottdiener, Bonow, & Epstein, 2010). 
Additionally, short comings with M-mode echocardiography have been cited in the 
literature (to include image quality or delineation of the edges, angularity, and ensuring 
that the plane of measurement passes through the largest dimension of the LV 
chamber), which may have added to the overall error seen in this study and served to 
reduce the overall significance of the M-mode measurements (Schiller & Foster, 1996; 
Sahn, DeMaria, Kisslo, & Weyman, 1978).  Nevertheless, the decrease seen in the 
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indexes in the derived 2-D echocardiograms combined with histological data gives 
strong evidence of hypertrophic cardiomyopathy. 
Additional Observations of Sarin’s Effects on the Heart  
Dobutamine Stress Testing  
In order to test stimulated heart function in mice, a low dose (1 mg/kg) of 
dobutamine was injected.  Dobutamine, a short acting nonselective β1 adrenergic 
agonist (Anderson, Moore, & Larson, 2008), increases heart rate, contractility, and 
cardiac output (Wiesmann, et al., 2001).  Measurements were made by 
echocardiography and ECG before and after the drug and two-way ANOVA did not 
demonstrate a significant difference in the interaction between dobutamine x sarin 
group x controls (for any parameter).  Therefore, dobutamine produced similar 
increases in heart rate and cardiac output in both sarin and controls, indicating that the 
β1 adrenoreceptor cascade was intact and that the sarin mice had adequate cardiac 
reserve to respond to the dobutamine stimulus.   
The ECG PR Interval 
  The PR interval in the 0.5 LD50 group was significantly increased after 
dobutamine infusion.  On the ECG, the PR interval is an indicator of AV conduction time.  
Lengthening of the PR interval can represent a host of cardiac problems (including 
ischemia) and can be attributed to ischemia, conduction and/or neurological 
dysfunction (Mirvis & Goldberger, 2008).  Because PR segment lengthening only 
occurred in 0.5 LD50 group, it is not known if this is related to an early onset of another 
delayed sarin effect or if it is an artifact of the small sample size (n = 5).  Moreover, this 
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study did not evaluate the conduction system, autonomic nervous system, or atriums; 
further study is needed to evaluate the conduction system and atria/ventricle timings 
before the implications of this finding are known.  
Limitations of this Study 
 Seven of the 12 mice from the 0.5 LD50 group died following the second sarin 
injection.  This severely limited statistical power in the ANOVA where the 0.5 LD50 group 
was included.  More importantly, it is possible that the mice that were able to survive 
the second injection were more resistant to sarin, and this group was selectively biased; 
additionally, the stress from the convulsions may have created secondary pathologies in 
this group. 
 The increased ESA and EDA, and the differences between the week 4 and 10 
results in 0.5 LD50 groups remain unclear.  Moreover, in the absence of histology (esp. in 
weeks two and four), it is not possible to ascertain whether the differences seen in the 
ventricular areas are causative, resultant, or extrinsic of the aforementioned pathology.  
Similarly, the death of half the mice in the 0.5 LD50 after the second injection may have 
selectively created a group of mice resistant to sarin’s effect, or pathologies in this 
group not seen in the 0.4 LD50 group.   
 Finally, the current data does not give indication as to the cause of the 
remodeling or pathology (whether a direct response to a cardiac insult or an indirect 
response to performance degradation of the autonomic or conduction system).  The 
current literature has expressed pathology in the brain and autonomic nervous system 
degradation following sarin exposure.  Autonomic changes in humans following the 
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Tokyo subway attack have shown by Yokoyama et al., and in rats following a single 
whole body dose of sarin (Yokoyama, et al., 1998, pp. 317 - 323; Yokoyama, et al., 1998, 
pp. 249 - 256; Grauer, et al., 2008).  Likewise, Morris et al. have demonstrated 
significant deviations in heart rate variability (HRV) in mice exposed to sarin that suggest 
these changes in the brain and autonomic nervous system affect the heart (Morris, Key, 
& Farah, 2007).  Nevertheless, it is possible that the cardiomyopathy is a direct effect of 
a change to the heart rather than the central nervous system (conduction system, e.g.).  
Therefore, further study is needed to determine the cause/origin of the cardiac 
dysfunction; perhaps using more robust methods such as polymerase chain reaction 
(PCR) and implanted ECG probes that allow for continuous recording. 
Future Work 
 As described above, the mechanism of sarin’s action on the cardiac system is 
unknown.  Understanding, the mechanism of action can help develop effective 
treatment regimes following a known or expected exposure (i.e. accident, split-MOPP 
decision, munitions demolition, etc).  Similarly, drugs such as propranolol are known to 
protect the heart in some instances (such as hypertension).  Thus, there is a need for 
further study that is focused on determining mechanisms of action and treatment 
techniques.  
Furthermore, the effects of treatment (atropine and palidoxime chloride or 2-
PAM) have not been studied and the pathology of sarin (or lack of pathology) following 
treatment has not been investigated.  Additional study is needed to determine if 
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atropine and 2-PAM are an effective long-term treatment, or if supplementary medical 
care is needed to treat the long-term effects demonstrated in this study. 
Conclusion 
 The preponderance of evidence in this study indicates delayed onset of 
morphology and reduced cardiac function of mice exposed to the nerve agent, sarin.  
Histology gives strong evidence of left ventricular cardiomyopathy and remodeling 
(possibly hypertrophy) by means of increased heart weight, cell size, natriuretic 
peptides production, and a reduction of ventricular area.  ECGs under dobutamine stress 
give evidence of ischemia and decreased cardiac performance as a result of the sarin 
exposures.  Similarly, in the later weeks of the experiment (weeks 4 and 10), the sarin 
mice demonstrated reductions the echocardiograph performance parameters (aFS, Vcf, 
and aFS/MPI) in the left ventricle; these mice showed signs of increased stress (volume 
overload, pressure, etc) as the ventricle areas (ESA and EDA) were enlarged.   
The ECG results present as nearly normal before dobutamine stressing; after 
dobutamine stressing the ECG shows significant detriment to cardiac performance.  This 
insidious nature of the sarin pathology has far reaching military implications.  A military 
member who had been exposed to an asymptomatic dose of sarin (possibly without 
knowledge) could show near normal cardiac parameters on a routine check-up yet could 
have a severe cardiac reaction to physiological stress.  Moreover, symptoms may not 
present until well after the post deployment health assessment that is currently 
required for all military personnel upon returning from a deployment.    
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Finally, these observations coincide with other observations of pathology seen in 
literature of sarin and organophosphate toxicology.  Additionally, the cardiomyopathy 
described here is in line with studies performed by Haley et al. in Gulf war veterans.  The 
studies gave evidence of altered diurnal patterns of heart rate and HRV correlated to 
reduced parasympathetic drive to the heart, possibly resulting from damage to the CNS 
(Haley, et al., 2004; Haley, Fleckenstein, Marshall, McDonald, Kramer, & Petty, 2000).  
Although it is unlikely that Gulf War Illness can ever be directly linked to sarin, this study 
along with similar studies in the literature present compelling need for continued 
investigation of the low dose toxicological effects of sarin.  
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Appendix A: Tabulated Average Results of Controls, 0.4 LD50, and 0.5 LD50 
Groups 
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Tabulated Results of Weights and Heart Section Measurements 
Table 1 Tabulated Results of Average Percent Changes in Body Weight 
 Control 0.4 LD50 0.5 LD50 
Baseline Body Wt. (g) 30.8 ± 0.6 29.6 ± 0.4 29.4 ± 0.5 
% Change at 24 Hr  -0.027 ± 0.3 -2.50 ± 0.54 -5.5 ± 1.6* 
% Change 4 WK 10.2 ± 1.5 6.8 ± 1.4 9.5 ± 1.3 
% Change 7 Wk 6.4 ± 0.7 3.1 ± 2.8 5.0 ± 1.7 
% Change 10 WK 8.6 ± 0.8 10.7 ± 4.0 9.6 ± 1.3 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
 
Table 2 Tabulated Results of Average Body Weight 
 Control 0.4 LD50 0.5 LD50 
Baseline Body Wt. (g) 30.8 ± 0.6 29.6 ± 0.4 29.4 ± 0.5 
24 Hr After Sarin (g) 30.8 ± 0.6 28.9 ± 0.4** 27.8 ± 0.3† 
4 WK Body Wt. (g) 34.0 ± 0.9 30.8 ± 0.4** 30.4 ± 0.2** 
7 Wk Body Wt. (g) 36.2 ± 0.9 31.8 ± 0.9** 31.9 ± 0.8* 
10 WK Body Wt. (g) 39.3 ± 1.2 35.2 ± 0.8 35.0 ± 1.2 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
 
Table 3 Tabulated Results of Week 10 Average Body Weights, Heart Weights, and 
Corrected Heart Weights (Heart Weight/Body Weight) 
 Control 0.4 LD50 0.5 LD50 
Body Weight (grams) 38.2 ± 1.2 34.9 ± 1.2   36.0 ± 1.5 
Heart Weight (grams) 0.152 ± 0.004 0.156 ± 0.003 0.166 ± 0.007 
Corrected Heart Weights (4.02  ± 0.2) X 10-3 (4.49  ± 0.1) X 10-3 (4.64  ± 0.2) X 10-3 
Corrected Heart Weights 
(Combined Data) 
(4.02  ± 0.21) X 10-3 (4.55  ± 0.11) X 10-3* 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
 
Table 4 Tabulated Results of the Heart Areas in Square Millimeters 
 Control 0.4 LD50 0.5 LD50 
LV Area (cm2) 3.60 ± 0.3 1.83 ± 0.3** 1.82 ± 0.5** 
RV Area (cm2) 1.51 ± 0.3 0.92 ± 0.2 0.62 ± 0.1 
Total Heart Area (cm2) 24.5 ± 1.0 23.6 ± 0.8 24.8 ± 1.0 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
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Tabulated Results of Echocardiograms 
Table 5 Tabulated Results of 2-Dimensional Echocardiograph Data 
 Control 0.4 LD50 0.5 LD50 
 
Before 
Dobutamine 
After 
Dobutamine 
Before 
Dobutamine 
After 
Dobutamine 
Before 
Dobutamine 
After 
Dobutamine 
Week 2 Results 
EDA (cm) 0.176 ± 0.008 0.136 ± 0.003 0.159 ± 0.009 0.120 ± 0.009 0.187 ± 0.004 0.141 ± 0.006 
ESA (cm) 0.128 ± 0.004 0.054 ± 0.007 0.114 ± 0.007 0.062 ± 0.009 0.143 ± 0.007 0.055 ± 0.006 
Area FS  0.260 ± 0.031 0.593 ± 0.056 0.286 ± 0.014 0.488 ± 0.047 0.234 ± 0.028 0.606 ± 0.036 
Week 4 Results 
EDA (cm) 0.142 ± 0.003 0.118 ± 0.005 0.152 ± 0.006 0.115 ± 0.003 0.162 ± 0.006 0.132 ± 0.011 
ESA (cm) 0.091 ± 0.003 0.060 ± 0.004 0.105 ± 0.005* 0.058 ± 0.003 0.112 ± 0.008* 0.075 ± 0.007 
Area FS  0.359 ± 0.015 0.494 ± 0.026 0.309 ± 0.016 0.490 ± 0.026 0. 310 ± 0.027 0.426 ± 0.036 
Week 10 Results 
EDA (cm) 0.155 ± 0.006 0.137 ± 0.005 0.187 ± 0.007** 0.154 ± 0.007 0.154 ± 0.003 0.137 ± 0.004 
ESA (cm) 0.108 ± 0.007 0.082 ± 0.005 0.143 ± 0.006† 0.097 ± 0.006 0.103 ± 0.005 0.079 ± 0.006 
Area FS  0.310 ± 0.021 0.399 ± 0.026 0.235 ± 0.013** 0.365 ± 0.028 0.331 ± 0.021 0.421 ± 0.041 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
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Table 6 Tabulated Results of M-Mode Echocardiograph Data 
 Control 0.4 LD50 0.5 LD50 
 
Before 
Dobutamine 
After 
Dobutamine 
Before 
Dobutamine 
After 
Dobutamine 
Before 
Dobutamine 
After 
Dobutamine 
Week 2 Results 
Heart Rate 
(bpm) 
472 ± 24 523 ± 14 498 ± 16 555 ± 11 481 ± 23 531 ± 29 
PWT (cm) 0.083 ± 0.007 0.101 ± 0.004 0.093 ± 0.004 0.114 ± 0.007 0.105 ± 0.008 0.108 ± 0.006 
SWT (cm) 0.089 ± 0.005 0.102 ± 0.004 0.090 ± 0.003 0.114 ± 0.005 0.090 ± 0.006 0.110 ± 0.008 
EDD (cm) 0.371 ± 0.018 0.303 ± 0.010 0.377 ± 0.017 0.285 ± 0.007 0.374 ± 0.012 0.305 ± 0.015 
ESD (cm) 0.238 ± 0.015 0.141 ± 0.010 0.266 ± 0.016 0.134 ± 0.007 0.250 ± 0.009 0.130 ± 0.007 
FS 0.309 ± 0.014 0.537 ± 0.024 0.299 ± 0.017 0.529 ± 0.020 0.331 ± 0.027 0.602 ± 0.030 
RWT 0.477 ± 0.044 0.675 ± 0.031 0.498 ± 0.031 0.809 ± 0.055 0.522 ± 0.046 0.726 ± 0.054 
Week 4 Results 
Heart Rate 
(bpm) 
508 ± 19 630 ± 20 510 ± 17 630 ± 33 552 ± 27 656 ± 29 
PWT (cm) 0.106 ± 0.003 0.114 ± 0.003 0.096 ± 0.003 0.110 ± 0.002 0.097 ± 0.003 0.109 ± 0.004 
SWT (cm) 0.104 ± 0.003 0.120 ± 0.002 0.099 ± 0.001 0.120 ± 0.003 0.109 ± 0.004 0.120 ± 0.001 
EDD (cm) 0.371 ± 0.005 0.322 ± 0.014 0.374 ± 0.008 0.309 ± 0.009 0.375 ± 0.013 0.318 ± 0.013 
ESD (cm) 0.233 ± 0.011 0.163 ± 0.014 0.233 ± 0.005 0.149 ± 0.013 0.236 ± 0.004 0.160 ± 0.019 
FS 0.373 ± 0.022 0.493 ± 0.030 0.375 ± 0.015 0.521 ± 0.034 0.369 ± 0.017 0.500 ± 0.041 
RWT 0.568 ± 0.020 0.742 ± 0.037 0.526 ± 0.021 0.751 ± 0.024 0.558 ± 0.027 0.727 ± 0.033 
Week 10 Results 
Heart Rate 
(bpm) 
435 ± 14 525 ± 16 394 ± 12 491 ± 13 407 ± 23 457 ± 18 
PWT (cm) 0.097 ± 0.004 0.108 ± 0.003 0.098 ± 0.003 0.110 ± 0.003 0.100 ± 0.003 0.116 ± 0.003 
SWT (cm) 0.103 ± 0.003 0.110 ± 0.002 0.098 ± 0.005 0.105 ± 0.003 0.106 ± 0.003 0.113 ± 0.003 
EDD (cm) 0.379 ± 0.008 0.341 ± 0.008 0.387 ± 0.006 0.326 ± 0.011 0.390 ± 0.012 .0339 ± 0.013 
ESD (cm) 0.229 ± 0.014 0.154 ± 0.007 0.256 ± 0.008 0.160 ± 0.011 0.229 ± 0.010 0.163 ± 0.012 
FS 0.400 ± 0.026 0.550 ± 0.014 0.340 ± 0.015 0.513 ± 0.022 0.413 ± 0.014 0.522 ± 0.021 
RWT 0.530 ± 0.022 0.645 ± 0.024 0.453 ± 0.037 0.668 ± 0.025 0.530 ± 0.026 0.682 ± 0.030 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
76 
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Table 7 Tabulated Results of Pulsed-Wave Doppler Data & Derived Parameters 
 Control 0.4 LD50 0.5 LD50 
 
Before 
Dobutamine 
After Dobutamine 
Before 
Dobutamine 
After 
Dobutamine 
Before 
Dobutamine 
After 
Dobutamine 
Week 2 Results 
Ao VTI  0.004 ± 0.000 0.004 ± 0.000 0.004 ± 0.000 0.005 ± 0.000 0.004 ± 0.000 0.004 ± 0.000 
ET (ms) 41.9 ± 2.3 36.2 ± 1.4 42.1 ± 1.6  35.2 ± 1.2 44 ± 1.3 38.1 ± 2.4 
ICT+IVRT (ms) 66.6 ± 3.3 56.4 ± 2.5 67.0 ± 3.1 52.8 ± 2.5  69.1 ± 2.1 60.9 ± 5.0 
Ao VMax 0.151 ± 0.014 0.169 ± 0.009 0.148 ± 0.011 0.182 ± 0.009 0.122 ± 0.002 0.160 ± 0.016 
FS/MPI 0.168 ± 0.026 0.394 ± 0.045 0.180 ± 0.008 0.339 ± 0.041 0.150 ± 0.017 0.475 ± 0.096 
Vcf (1/s) 6.33 ± 0.78 16.54 ± 1.69 6.83 ± 0.0344 13.91 ± 1.21 5.31 ± 0.51 16.29 ± 1.59 
Week 4 Results 
Ao VTI 0.003 ± 0.000 0.004 ± 0.000 0.004 ± 0.000 0.004 ± 0.000 0.003 ± 0.000 0.004 ± 0.000 
ET (ms) 40.2 ± 1.5 34.2 ± 1.4 41.9 ± 2.2 36.6 ± 1.8 41.7 ± 2.8 35.2 ± 1.8 
ICT+IVRT (ms) 56.2 ± 2.8 47.6 ± 1.8 61.3 ± 3.7 49.6 ± 2.8 58.3 ± 3.4 44.9 ± 1.9 
Ao VMax 0.108 ± 0.005 0.142 ± 0.015 0.123 ± 0.009 0.174 ± 0.021 0.108 ± 0.006 0.166 ± 0.018 
FS/MPI 0.261 ± 0.014 0.354 ± 0.017 0.215 ± 0.014* 0.360 ± 0.015 0.22 ± 0.014* 0.334 ± 0.026 
Vcf (1/s) 9.06 ± 0.47 14.92 ± 1.15 7.65 ± 0.58 13.91 ± 1.14 7.64 ± 1.06  12.28 ± 1.24 
Week 10 Results 
Ao VTI 0.004 ± .000 0.004 ± 0.000 0.005 ± 0.000 0.005 ± 0.001 0.004 ± 0.000 0.005 ± 0.000 
ET (ms) 45.4 ± 1.3 38.1 ± 1.2 50.3 ± 2.1 40.4 ± 1.9 52.1 ± 1.9 46.9 ± 1.7** 
ICT+IVRT (ms) 71.6 ± 2.3 56.5 ± 1.8 79.0 ± 2.5 65.3 ± 3.4* 80.1 ± 5.7 70.6 ± 3.7* 
Ao VMax 0.113 ± 0.013 0.146 ± 0.009 0.129 ± 0.010 0.158 ± 0.013 0.122 ± 0.007 0.136 ± 0.008 
FS/MPI 0.200 ±0.012 0.271 ± 0.022 0.150 ± .008** 0.225 ± 0.015 0.218 ± 0.016 0.283 ± 0.036 
Vcf (1/s) 7.08 ± 0.56 10.58 ± 0.90 4.77 ± 0.40** 9.32 ± 0.92 6.36 ± 0.43 9.01 ± 0.79 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
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Tabulated Results of ECG Data Analysis 
Table 8 Tabulated Results of ECG Telemetry 
 Control 0.4 LD50 0.5 LD50 
 
Before 
Dobutamine 
After Dobutamine 
Before 
Dobutamine 
After 
Dobutamine 
Before 
Dobutamine 
After 
Dobutamine 
RR Interval (ms) 152.8 ± 4.3 112.7 ± 9.5  153.4 ± 4.8 115.5 ± 2.6 158.4 ± 12.1 128.0 ± 7.2 
Heart Rate (bpm) 395.2 ± 11.2 553.6 ± 36.5 394.6 ± 13.0 521.8 ± 11.9 387.6 ± 29.0 474.5 ± 26.4 
QRS (ms) 16.5 ± 0.8 17.3 ± 0.9 18.2 ± 1.0 19.5 ± 1.1 17.0 ± 1.4 19.2 ± 1.4 
PR Interval (ms) 42.9 ± 1.4  39.0 ± 2.7 42.0 ± 1.1 44.2 ± 2.3 48.3 ± 3.3 56.5 ± 5.6** 
P Width (ms) 12.6 ± 0.7 11.8 ± 0.6 14.2 ± 1.2 14.6 ± 0.9 13.2 ± 0.6 14.7 ± 0.4 
QT Interval (ms) 54.6 ± 7.0 59.4 ± 7.2 57.5 ± 1.3 64.3 ± 2.4 61.3 ± 4.4 64.8 ± 4.5 
QTC 44.2 ± 1.8 56.5 ± 1.6 46.5 ± 1.0 59.8 ± 1.8 48.7 ± 2.6 57.1 ± 3.0 
TC Interval (ms) 17.3 ± 1.1 25.9 ± 1.5 24.0 ± 1.7 35.0 ± 1.8** 22.4 ± 4.2 33.1 ± 1.7* 
STC Length (ms) 7.8 ± 2.0 6.7 ± 1.9 11.7 ± 0.8 13.2 ± 1.4* 12.7 ± 3.2 7.0 ± 2.1* 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
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Tabulated Results of Histology: ANP/BNP Quantification 
 
Table 9 Tabulated Results of the Average ANP Expressed as the Natural Log of the Average Percent in Each Area 
 Control 0.4 LD50 0.5 LD50 
LV Wall 12.6 ± 2.7 27.2 ± 4.7* 17.1 ± 3.4 
Septum 11.2 ± 2.7 22.2 ± 4.0* 8.1 ± 1.4 
RV Wall 15.4 ± 3.4 27.4 ± 7.5 21.7 ± 7.5 
LV Total (Wall +Septum) 11.9 ± 2.5 24.7 ± 4.2* 12.6 ± 2.4 
ANP Total 13.1 ± 2.6 25.6 ± 5.1 15.6 ± 3.4 
Sarin Groups Combined ANP Combined Data 
LV Wall 12.6 ± 2.7 23.0 ± 3.3* 
Septum 11.2 ± 2.7 15.1 ± 3.1 
RV Wall 15.4 ± 3.4 24.6 ± 5.0 
LV Total (Wall +Septum) 11.9 ± 2.5 18.3 ± 3.1 
ANP Total 13.1 ± 2.6 20.6 ± 3.5 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
 
Table 10 Tabulated Results of the Average BNP Expressed as the Average Percent of BNP 
in Each Area 
 Control 0.4 LD50 0.5 LD50 
LV Wall 11.1 ± 1.8 27.3 ± 3.9 19.1 ± 6.5 
Septum 11.8 ± 3.4 18.2 ± 3.6 8.7 ± 2.4 
RV Wall 10.1 ± 1.4 19.0 ± 5.5 19.0 ± 7.0 
LV Total (Wall +Septum) 11.5 ± 2.4 22.7 ± 3.5* 13.9 ± 4.0 
BNP Total 11.0 ± 1.7 21.5 ± 3.6 15.6 ± 4.8 
Sarin Groups Combined BNP Combined Data 
LV Wall 11.1 ± 1.8 23.2 ± 3.5* 
Septum 11.8 ± 3.4 13.5 ± 2.5 
RV Wall 10.1 ± 1.4 19.0 ± 3.8 
LV Total (Wall +Septum) 11.5 ± 2.4 18.3 2.3 
BNP Total 11.0 ± 1.7 18.5 ± 3.8* 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
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Tabulated Results of Cell Size Quantification from H&E Staining, Collagen 
Quantification from Picrosirius Red Staining 
 
Table 11 Tabulated Results of Cell Size in the Left Ventricle Expressed as Pixels/Nuclei 
 Control 0.4 LD50 0.5 LD50 
LV Wall 4544 ± 274 4726 ± 308 4664 ± 254 
Septum 3890 ± 232 4678 ± 356 5011 ± 371 
LV Total (Wall +Septum) 4291 ± 272 4643 ± 216 4837 ± 287 
Sarin Groups Combined Cell Size Data 
LV Wall 4544 ± 274 4817 ± 252* 
Septum 3890 ± 232 4599 ± 180 
LV Total (Wall +Septum) 4291 ± 272 4724 ± 168 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
 
Table 12  Tabulated Results of Collagen in the Heart Expressed as a Ratio of Pixels 
Stained with Sirius Red to Total Heart Area (Pixels) 
 
Control 0.4 LD50 0.5 LD50 
Total 0.00103 ± (8 X 10-5) 0.00102 ± (2.7 X 10-4) 0.000952 ± (9.6 X 10-5) 
All values are expressed as the Mean ± SE 
*   p < 0.05 when compared to controls, ** p < 0.01 when compared to controls, † p < 0.001 when compared to controls 
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Appendix B: Unpublished Heart Weight Data  
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Heart Weight Data (Unpublished Study) 
20 male C57BL/6J mice were housed individually at 22°C with a 12:12-hour dark-
light cycle. Mice had free access to a standard diet and tap water. Mice were injected 
with sarin: 64µg/kg 0.4 LD50 or saline (control group) on two consecutive days.  Each 
group (controls, 0.4 LD50) consisted of ten mice.  Mice body weights, heart weights, and 
kidney weights were collected 8 weeks following the sarin injections.  Heart weights 
normalized to kidney weights are a superior indicator of abnormal heart growth because 
kidneys weights do not fluctuate with diet or as much as body weights.  In the study 
presented in this thesis, kidney weights were not collected so this data is only available 
from this separate unpublished study.  
 
Figure 70 Unpublished Heart Weight to Body Weight Data 
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Figure 71 Unpublished Heart Weight to Kidney Weight Data 
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